

=> d his


(FILE 'HOME' ENTERED AT 07:57:59 ON 21 DEC 2008)

FILE 'REGISTRY' ENTERED AT 07:58:16 ON 21 DEC 2008

L1 STRUCTURE UPLOADED
 L2 27 S L1
 L3 1 S PIPERAZINE/CN
 L4 1425189 S 46,383/RID
 L5 367 SEARCH L1 SSS SUB-L4 FULL

=> d que 15 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L4 1425189 SEA FILE=REGISTRY ABB=ON PLU=ON 46,383/RID
 L5 367 SEA FILE=REGISTRY SUB=L4 SSS FUL L1

100.0% PROCESSED 743 ITERATIONS 367 ANSWERS
 SEARCH TIME: 00.00.01

=> s 15 and ed<6/12/2002

40504727 ED<6/12/2002
 (ED<20020612)

L6 238 L5 AND ED<6/12/2002

=> s 16 and caplus/lc

61403079 CAPLUS/LC


L7 235 L6 AND CAPLUS/LC

=> s 16 not 17

L8 3 L6 NOT L7

=> d 1-3 ide can


LA NUMBER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 210015-46-5 REGISTRY
 SD Entered STN ON Sep 1998
 CN 2-Piperazinecarboxamide, 4-(2-aminomethyl)-1-[[4-(4-chlorobenzoyl)-1-piperidinylsulfonyl]-N-hydroxy- (CA INDEX NAME)
 OTHER CA INDEX NAME:
 CA 2-Piperazinecarboxamide, 4-(2-aminomethyl)-1-[[4-(4-chlorobenzoyl)-1-piperidinylsulfonyl]-N-hydroxy- (CCL)
 MF C12 H20 Cl N6 O5
 CI COM
 SR CA



***PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT**


LA NUMBER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 210015-48-5 REGISTRY
 SD Entered STN ON Sep 1998
 CN 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[[4-(4-chlorobenzoyl)-1-piperidinylsulfonyl]-N-hydroxy- (CA INDEX NAME)
 OTHER CA INDEX NAME:
 CA 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[[4-(4-chlorobenzoyl)-1-piperidinylsulfonyl]-N-hydroxy- (CCL)
 MF C22 H32 Cl N6 O5
 CI COM
 SR CA

Absolute stereochemistry:



***PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT**

LA NUMBER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 210015-52-6 REGISTRY
 SD Entered STN ON Sep 1998
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinylsulfonyl]-N-hydroxy- (CA INDEX NAME)
 MF C17 H20 Cl N6 O5
 CI COM
 SR CA



***PROPERTY DATA AVAILABLE IN THE "PROP" FORMAT**

=> fil capl
FILE 'CAPLUS' ENTERED AT 08:03:47 ON 21 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 19 Dec 2008 (20081219/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>
'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s 15

19 ANKER 1 OF 17 CAPLUS CONFIDENT 2008 ACS ON STN (Continued)

AK 2006 972330 CAPLUS

TR 146-64133

TI Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: piperazine, piperidine and diazepam hydroxamic acid analogs

AD Gupta, S. P. S. Kumar, S.

CS Department of Chemistry, Birla Institute of Technology and Science,

Pilani, SONGA, India

50 Asian Journal of Biochemistry (2006), 1(3), 211-213

6008 143300, ISSN 1518-9903

PS Academic Journals

LA Journal

AS BioLib

A quantitative structure-activity relationship study has been made on four different series of piperazine, piperidine and diazepam hydroxamic acid analogs acting as matrix metalloproteinase (MMP) inhibitors. The results suggest that in part of the cases the hydrophobic property of the moieties plays a major role in the inhibition of the enzymes MMP-1, MMP-2, MMP-13 and MMP-9. In most cases, MMP-9 and MMP-13 are shown to behave in a similar fashion with the different group of inhibitors.

IT 60016-06-6 60016-07-2 60016-08-0

60016-09-1 60017-00-1 60017-06-6

60017-06-0 60017-06-1 60017-06-2

60017-06-3 60017-06-4 60017-06-5

60017-06-6 60017-08-0 60017-11-0

60017-12-1 60017-12-2 60017-14-3

60042-10-3


RE DNA (Drug mechanism of action); PAC (Pharmacological activity); PBP (Protein); TSD (Therapeutic use); SDA (Sociological study); SDS (Drug)

NCAR studies on piperazine, piperidine and diazepam hydroxamic acid analogs acting as matrix metalloproteinase inhibitors

IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, N-hydroxy-3-methyl-1-[[4-[(2-phenylmethoxy)phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-07-2 CAPLUS

ON 2-Piperazinecarboxamide, N-hydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-08-0 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60017-00-1 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(4-isquinolinylmethoxy)phenyl]sulfonyl]-3-methyl-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60017-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(4-quinolinylmethoxy)phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60017-06-0 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.




IN 60017-06-2 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-trifluoromethylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



19 ANKER 1 OF 17 CAPLUS CONFIDENT 2008 ACS ON STN (Continued)



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)


Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.



IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.




IN 60016-06-6 CAPLUS

ON 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (IR, SS)- (CA INDEX NAME)

Absolute stereochemistry.




19 ANKER 1 OF 17 CAPLUS OMPRIGHT 2009 ACS on STN (Continued)



IN 600617-06-3 CAPLUS
CN 2-[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-, (R,S)- (CA INDEX NAME)

Absolute stereochemistry



IN 600617-07-4 CAPLUS
CN 2-[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-, (R,S)- (CA INDEX NAME)


Absolute stereochemistry



19 ANKER 1 OF 17 CAPLUS OMPRIGHT 2009 ACS on STN (Continued)


IN 600617-10-9 CAPLUS
CN 2-[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-, (R,S)- (CA INDEX NAME)

Absolute stereochemistry



IN 600617-11-0 CAPLUS
CN 1-[3-[[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-1,4-dihydro-2H-1,2,4-triazole-4-carboxamide], (R,S)- (CA INDEX NAME)

Absolute stereochemistry




IN 600617-12-1 CAPLUS
CN 1-[3-[[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-1,4-dihydro-2H-1,2,4-triazole-4-carboxamide], (R,S)- (CA INDEX NAME)

Absolute stereochemistry




19 ANKER 1 OF 17 CAPLUS OMPRIGHT 2009 ACS on STN (Continued)




IN 600617-06-3 CAPLUS
CN 2-[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-, (R,S)- (CA INDEX NAME)

Absolute stereochemistry




IN 600617-06-6 CAPLUS
CN 2-[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-, (R,S)- (CA INDEX NAME)

Absolute stereochemistry




19 ANKER 1 OF 17 CAPLUS OMPRIGHT 2009 ACS on STN (Continued)




IN 600617-10-3 CAPLUS
CN 1-[3-[[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-1,4-dihydro-2H-1,2,4-triazole-4-carboxamide], (R,S)- (CA INDEX NAME)

Absolute stereochemistry



IN 600617-14-3 CAPLUS
CN 1-[3-[[2-((1-((2-methyl-3-pyridyl)methoxy)phenyl)sulfonyl)-4-(4-methylphenyl)methyl]-5-hydroxy-3-methyl-1-[[4-[(2-methyl-3-pyridyl)methoxy]phenyl]sulfonyl]-1,4-dihydro-2H-1,2,4-triazole-4-carboxamide], (R,S)- (CA INDEX NAME)


Absolute stereochemistry



[9] ANSWER 1 OF 17 CAPILLAS COPYRIGHT 2008 ACS on STN (Continued)

IN 901443-23-0 CASUS
CN 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(3-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-, (2R,5S)- (CA INDEX NAME)

Absolute stereochemistry




RE: CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE EE FORMAT

L9 ANSWER 2 OF 17 CAPLIS COPYRIGHT 2008 ACS on STN

IN	2006-207888	CASLES
IN	140-207885	
IN	Stabilization of the autopolymers of TMFAc converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies	
AI	Ingole, Richard M.; Oeth, Peter; Strickland, Corey L.; Le, Xing Y.; Madison, Vincent; Beyer, Brian M.	
CS	Department of Structural Chemistry, Goehring-Pfau Research Institute, Kemnath, NJ, 08653, USA	
PS	Protein Engineering, Design & Selection (PDSE), 19(4), 161-161	
PS	00009	162008, ISSN 1524-1910/06
PS	Oxford University Press	
PS	Journal	
PS	English	

[illegible]

IT that is suitable for inhibitor soaking and structure determination
911294-08-3
HL: RSU (Biological study, unclassified); B30L (Biological study)
(Inhibition: mutation stabilization of the autoprotoleolysis of
TNF- α converting stamper (TACE) results in a novel crystal form)
RN 911294-08-3 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[[4-(phenylmethoxy)phenyl]sulfonyl]-
(CA INDEX NAME)



RE CNT 23 THREE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

IX 2006 465024 CLUS
 IN 143-394966
 II Prevention of progressive joint destruction in adjuvant induced arthritis
 in rats by a novel matrix metalloproteinase inhibitor, PZ2139-69. [Erratum
 corrected cited in CAS 2006 15:143-394966]
 AN Ishikawa, A.; Kakehi, N.; Nishigaki, M.; Naya, M.; Suenomi, H.; Yoshitaka,
 M.; Minoura, K.; Kato, I.; Inanishi, J.; Kono, Y.; Maruta, T.; Muramatsu, T.; Suzuki,
 I.; Imamura, Y.; Yoshimasa, O.; Yoshitaka, M.; Matsui, S.; Saito,
 CS Medicinal Biochemistry Research Laboratories, Fujisawa Pharmaceutical Co.,
 Ltd., Yodogawa-ku, Osaka, 572-8516, Japan
 SO European Journal of Pharmacology (2006), 515(1-3), 398

OGDN EJPM22, ISSN: 0014-2999
 Elsevier B.V.
 IT Journal
 LA English
 AB The Acknowledgment was omitted from the printed version; it should read:
 The authors thank Dr. Nobuhisa Yamamoto for advice and contribution to
 the enzyme inhibition assays.
 IT 945444-16-F, FR 217840
 RE PL CMC (Pharmacological activity); THU (Therapeutic use); BZOL
 (Biological probe); UNES (Uses)
 AB Inhibitor designed to protect destruction in antibiotic waste (Branatol)

WV 68644-10-6 CASUS
CN 2-Piperazinecarboxamide, 1-[[(5-(4-fluorophenyl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, [2S]- (CA INDEX NAME)
Absolute stereochemistry.

Absolute stereochemistry.



10 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS db STN

2006 69887 CAPLUS
142-529105
Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, P0217940
Ishikawa, Takeshi; Nishizaki, Fumio; Hirata, Sumiko; Hirayama, Yoshitaka; Minoura, Ryoko; Imanishi, Jun-ko; Naya, Masahiro; Kikuchi, Tsuyoshi; Imanaka, Yoshinaga; Okubo, Yoshitaka; Matsui, Satoru
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
European Journal of Pharmacology (2006), 508(1-3), 259-267
CODEN: EJPHAL; ISSN 0014-2999
Elsevier B.V.
Journal
Cellulose

[illegible]


IT 84844-16-6, PR 217840

RL: PAC (Pharmacological activity); THU (Therapeutic use); B30L (Biological study); V03S (Uses)
 MMF inhibitor prevents joint destruction in arthritic rats
 S48444-16-6 CAPLUS
 2-Phenylazapicarbonylamide, 1-[[[4-(4-fluorobenzyl)-2-thienyl]sulfonyl]-N-

ON 2-Phenylazobenzoxazole


hydroxy-4-(methylsulfonyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry




RE CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IN 63064-48-9 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[3,5-difluoro-4-(4-fluorophenyl)phenyl]sulfonyl]-N-hydroxy-], (S)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63064-49-8 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[3,5-difluoro-4-(4-fluorophenyl)phenyl]sulfonyl]-N-hydroxy-4-(4-morpholinylacetyl)-], (S)- (CA INDEX NAME)


Absolute stereochemistry.



IN 63064-50-1 CAPLUS
ON 2-Fluorobenzoic acid, 4-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-3-(hydroxymethyl)ethyl], ethyl ester, (S)- (CA INDEX NAME)


Absolute stereochemistry.

LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IN 63064-74-6 CAPLUS
ON 1,3-Piperazinecarboxamide, 4-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-N-[2-(1-pyrrolidinyl)ethyl]-], (S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 63064-75-4 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-3-(hydroxymethyl)ethyl], 2-(1-pyrrolidinyl)ethyl ester, (S)- (CA INDEX NAME)

Absolute stereochemistry.




LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IN 63064-71-4 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[3,5-difluoro-4-(4-fluorophenyl)phenyl]sulfonyl]-N-hydroxy-4-methyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63064-72-3 CAPLUS
ON 2-Fluorobenzoic acid, 4-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-3-(hydroxymethyl)-2-methoxyethyl ester, (S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 63064-73-4 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[(4-methyl-1-piperazinyl)acetyl]-], (S)- (CA INDEX NAME)

Absolute stereochemistry.

LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


IN 63064-76-7 CAPLUS
ON 2-Fluorobenzoic acid, 4-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-3-(hydroxymethyl)-N-methyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 63064-77-8 CAPLUS
ON 2-Fluorobenzoic acid, 4-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-3-(hydroxymethyl)-N,N-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63064-78-9 CAPLUS
ON 2-Fluorobenzoic acid, 1-[[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-(2-oxo-2-(1-pyrrolidinyl)ethyl)-], (S)- (CA INDEX NAME)


Absolute stereochemistry.



L9 ANDER 6 OF 17 CAPLIS COMPIRIST 2009 ACS on STN (Continued)


IN 63706-79-0 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-2-[(hydroxyamino)carbonyl]-1-methyl-4-piperidinyl ester, (SR)- (CA INDEX NAME)

Absolute stereochemistry




IN 63706-80-3 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry



IN 63706-81-4 CAPLIS
CN 2-Piperazinecarboxylic acid, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-methyl-1-piperazinyl)acetyl], (SR)- (CA INDEX NAME)


Absolute stereochemistry



L9 ANDER 6 OF 17 CAPLIS COMPIRIST 2009 ACS on STN (Continued)


IN 63706-84-7 CAPLIS
CN 2-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-2-[(hydroxyamino)carbonyl]-2-[(1-piperidinylethyl) ester, (SR)- (CA INDEX NAME)

Absolute stereochemistry




IN 63706-85-8 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(methylsulfonyl)], (SR)- (CA INDEX NAME)

Absolute stereochemistry



IN 63706-86-9 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-methoxyethyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry




IN 63706-87-0 CAPLIS

L9 ANDER 6 OF 17 CAPLIS COMPIRIST 2009 ACS on STN (Continued)


IN 63706-88-5 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry




IN 63706-89-6 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(1-piperidinyl)acetyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry



IN 63706-90-5 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)


Absolute stereochemistry



L9 ANDER 6 OF 17 CAPLIS COMPIRIST 2009 ACS on STN (Continued)


IN 63706-91-2 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry




IN 63706-92-1 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)

Absolute stereochemistry



IN 63706-93-2 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)


Absolute stereochemistry



IN 63706-94-3 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-morpholinyl)acetyl], (SR)- (CA INDEX NAME)


Absolute stereochemistry

19 ANKER 6 OF 17 CAPLUS COPYR18T 2008 ACS on STN (Continued)




IN 63706F-01-6 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[(4-pyridinyl)ethyl]sulfonyl]-, (Cl)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63706F-06-7 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[(2-oxo-2-(1-pyridinyl)acetyl)-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry



IN 63706F-06-8 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-(dimethylamino)sulfonyl]-N-hydroxy-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANKER 6 OF 17 CAPLUS COPYR18T 2008 ACS on STN (Continued)




IN 63706F-07-0 CAPLUS
CN 2-Piperazinacarbonic acid, 4-[[4-(4-chlorophenyl)sulfonyl]-5-[[4-(fluorophenyl)sulfonyl]-N-(2-methoxyethyl ester), (Cl)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63706F-08-0 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-(2-oxo-2-(2-phenylethyl)sulfonyl)-N-hydroxy-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.



IN 63706F-09-4 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-(4-piperidinylsulfonyl)-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry

19 ANKER 6 OF 17 CAPLUS COPYR18T 2008 ACS on STN (Continued)




IN 63706F-09-0 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[(1,1-dipiperidinylsulfonyl)amino]sulfonyl]-, (Cl)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63706F-09-0 CAPLUS
CN 4-Morpholinacarbonamide, N-[[[(Cl)-4-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-5-[[1,1-dipiperidinylsulfonyl]amino]sulfonyl]-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.



IN 63706F-09-0 CAPLUS
CN 2-Piperazinacarbonamide, 2-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-5-[[1,1-dipiperidinylsulfonyl]amino]sulfonyl]-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANKER 6 OF 17 CAPLUS COPYR18T 2008 ACS on STN (Continued)




IN 63706F-09-0 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-(1-oxo-2-propenyl)-, (Cl)- (CA INDEX NAME)

Absolute stereochemistry.



IN 63706F-09-0 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-(1-oxo-2-propenyl)-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.



IN 63706F-09-0 CAPLUS
CN 2-Piperazinacarbonamide, 1-[[4-(4-chlorophenyl)-5,5-difluorophenyl]sulfonyl]-N-hydroxy-4-(1-oxo-2-propenyl)-, (Cl)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANWER 6 OF 17 CAPLUS OMPRISET 2008 ACS ON STN (Continued)




IN 631061-06-3 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(4-methylphenyl)acetyl]-, GSK- (CA INDEX NAME)

Absolute stereochemistry.




IN 631061-06-4 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)

Absolute stereochemistry.




IN 631061-06-6 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)

19 ANWER 6 OF 17 CAPLUS OMPRISET 2008 ACS ON STN (Continued)




IN 631061-06-8 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)

Absolute stereochemistry.



IN 631061-09-9 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)

Absolute stereochemistry.




IN 631061-19-0 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)


19 ANWER 6 OF 17 CAPLUS OMPRISET 2008 ACS ON STN (Continued)

(CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




IN 631061-07-7 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,5-difluorophenyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridyl)acetyl]-, GSK- (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



Absolute stereochemistry.




Absolute stereochemistry




Absolute stereochemistry

LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(difluorophenyl]sulfonyl]-N-hydroxy-4-(3-propenyl)-, (S)- (CA INDEX NAME)


Absolute stereochemistry



Absolute stereochemistry




Absolute stereochemistry.




Absolute stereochemistry


LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

IN 637671-19-1 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-5,6-difluorophenyl]sulfonyl]-N-hydroxy-4-[[1,5-dichlorophenyl]methyl]sulfonyl]-, (S)- (CA INDEX NAME)

LE ANWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IN 637671-23-7 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-5,6-difluorophenyl]sulfonyl]-N-hydroxy-4-[[1,5-dichlorophenyl]methyl]sulfonyl]-, (S)- (CA INDEX NAME)

Absolute stereochemistry.

IN 637671-23-7 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-5,6-difluorophenyl]sulfonyl]-N-hydroxy-4-[[1,5-dichlorophenyl]methyl]sulfonyl]-, (S)- (CA INDEX NAME)

Absolute stereochemistry.

IN 637671-23-7 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-5,6-difluorophenyl]sulfonyl]-N-hydroxy-4-[[1,5-dichlorophenyl]methyl]sulfonyl]-, (S)- (CA INDEX NAME)

L9 ANKER 7 OF 17 CAPLUS OMPRISET 2009 ACS on STN (Continued)

AN 2000-041815 CAPLUS

IN 140-77055

TI Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

AI Chen, Jian; Jeffery, Sweeney; Nolan, Len; Knaflitz, Martin; Robert, L.; Kuhn, Keith A.; M. Hume, James; Chai, Praveen; Aggar, Hitesh; Mankiw, Anna; Kim, Yong; Garza, Krishna; Anzures, Humberto; Van Wart, Harold B.

CS Roche Biopharma, Palo Alto, CA, USA; IDA

DI Biocytogen & Medicinal Chemistry Letters (2000), 13(2), 2063-2064

DOI: 10.1021/1000-091X

PI Elsevier Science B.V.

PI Journal

LA English

AB CASREACT 140-77055

AB A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in acute animal models, and pharmacokinetic data are discussed.


IT 200007-21-8

RE PAC (Pharmacological activity); PEP (Pharmacokinetics); PEP (Preclinical); SPN (Synthetic preparation); SPN (Synthesis); SPN (Therapeutic use); SPN (Biological study); SPN (Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs)

IN 200007-21-8 CAPLUS

ON 2-Piperazinecarboxamide, 4-[[4-(4-fluorophenyl)-3,6-dihydro-1,2H-pyridin-3-ylidene]N-hydroxy-N,1'-dimethyl-], US- CA INDEX NAME

Absolute stereochemistry



IT 200011-20-3P 200011-21-8P 640466-06-8P

640466-09-3P 640466-11-3P 640466-14-8P

RE PAC (Pharmacological activity); PEP (Pharmacokinetics); SPN (Synthetic preparation); SPN (Therapeutic use); SPN (Biological study); PEP (Preparation); SPN (Use)

(Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs)

IN 200011-20-7 CAPLUS

ON 2-Piperazinecarboxamide, 1-[[4-(4-fluorophenyl)-3,6-dihydro-1,2H-pyridin-3-ylidene]N-hydroxy-N,2,2,3-tetrafluoroethyl-], US- CA INDEX NAME

Absolute stereochemistry



L9 ANKER 7 OF 17 CAPLUS OMPRISET 2009 ACS on STN (Continued)

AN 2000-039109 CAPLUS

IN 139-32229

TI Synthesis and biological activity of piperazine-based dual MMP-13 and TNF- α converting enzyme inhibitors

AI Letovic, Michael A.; Barbetta, John T.; Certe, Thomas J.; Hardick, Joel S.; Liras, Jennifer; Lopez-Murrow, Lori L.; Mitchell, Peter G.; Roe, Mark C.; Warren, Lisa K.; Dow, Sheri L.; Elm, Ethan J.; Switzer, Francis J.; Vaughn, Marilee L.; Yu, Chul H.

CS Orion Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA

DI Biocytogen & Medicinal Chemistry Letters (2000), 13(10), 3242-3246

DOI: 10.1021/1000-091X

PI Elsevier Science B.V.

PI Journal

LA English

AB CASREACT 139-32229

AB A series of novel MMP-13 and TNF- α converting enzyme inhibitors based on piperazine-2-carboxamide acid scaffolds are described. The TACE, MMP-1, and MMP-13 activity of these inhibitors as well as the effect of substitution of the piperazine nitrogen and the 2-1' benzyloxy tailpiece is discussed. Moderate in vivo activity is observed with several members of this group.

IT 600016-06-3P 600016-07-3P 600016-08-3P

600016-09-3P 600016-10-3P 600016-11-3P

600016-12-3P 600016-13-3P 600016-14-3P

600016-15-3P 600016-16-3P 600016-17-3P

600016-18-3P 600016-19-3P 600016-20-3P

600016-21-3P 600016-22-3P 600016-23-3P

600016-24-3P 600016-25-3P 600016-26-3P

600016-27-3P 600016-28-3P 600016-29-3P

600016-30-3P 600016-31-3P 600016-32-3P

600016-33-3P 600016-34-3P 600016-35-3P

600016-36-3P 600016-37-3P 600016-38-3P

600016-39-3P 600016-40-3P 600016-41-3P

600016-42-3P 600016-43-3P 600016-44-3P

600016-45-3P 600016-46-3P 600016-47-3P

600016-48-3P 600016-49-3P 600016-50-3P

600016-51-3P 600016-52-3P 600016-53-3P

600016-54-3P 600016-55-3P 600016-56-3P

600016-57-3P 600016-58-3P 600016-59-3P

600016-60-3P 600016-61-3P 600016-62-3P

600016-63-3P 600016-64-3P 600016-65-3P

600016-66-3P 600016-67-3P 600016-68-3P

600016-69-3P 600016-70-3P 600016-71-3P

600016-72-3P 600016-73-3P 600016-74-3P

600016-75-3P 600016-76-3P 600016-77-3P

600016-78-3P 600016-79-3P 600016-80-3P

600016-81-3P 600016-82-3P 600016-83-3P

600016-84-3P 600016-85-3P 600016-86-3P

600016-87-3P 600016-88-3P 600016-89-3P

600016-90-3P 600016-91-3P 600016-92-3P

600016-93-3P 600016-94-3P 600016-95-3P

600016-96-3P 600016-97-3P 600016-98-3P

600016-99-3P 600016-100-3P 600016-101-3P

600016-102-3P 600016-103-3P 600016-104-3P

600016-105-3P 600016-106-3P 600016-107-3P

600016-108-3P 600016-109-3P 600016-110-3P

600016-111-3P 600016-112-3P 600016-113-3P

600016-114-3P 600016-115-3P 600016-116-3P

600016-117-3P 600016-118-3P 600016-119-3P

600016-120-3P 600016-121-3P 600016-122-3P

600016-123-3P 600016-124-3P 600016-125-3P

600016-126-3P 600016-127-3P 600016-128-3P

600016-129-3P 600016-130-3P 600016-131-3P

600016-132-3P 600016-133-3P 600016-134-3P

600016-135-3P 600016-136-3P 600016-137-3P

600016-138-3P 600016-139-3P 600016-140-3P

600016-141-3P 600016-142-3P 600016-143-3P

600016-144-3P 600016-145-3P 600016-146-3P

600016-147-3P 600016-148-3P 600016-149-3P

600016-150-3P 600016-151-3P 600016-152-3P

600016-153-3P 600016-154-3P 600016-155-3P

600016-156-3P 600016-157-3P 600016-158-3P

600016-159-3P 600016-160-3P 600016-161-3P

600016-162-3P 600016-163-3P 600016-164-3P

600016-165-3P 600016-166-3P 600016-167-3P

600016-168-3P 600016-169-3P 600016-170-3P

600016-171-3P 600016-172-3P 600016-173-3P

600016-174-3P 600016-175-3P 600016-176-3P

600016-177-3P 600016-178-3P 600016-179-3P

600016-180-3P 600016-181-3P 600016-182-3P

600016-183-3P 600016-184-3P 600016-185-3P

600016-186-3P 600016-187-3P 600016-188-3P

600016-189-3P 600016-190-3P 600016-191-3P

600016-192-3P 600016-193-3P 600016-194-3P

600016-195-3P 600016-196-3P 600016-197-3P

600016-198-3P 600016-199-3P 600016-200-3P

RE CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE X9 POINT

L9 ANKER 7 OF 17 CAPLUS OMPRISET 2009 ACS on STN (Continued)

AN 2000-041815 CAPLUS

IN 140-77055

TI Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

AI Chen, Jian; Jeffery, Sweeney; Nolan, Len; Knaflitz, Martin; Robert, L.; Kuhn, Keith A.; M. Hume, James; Chai, Praveen; Aggar, Hitesh; Mankiw, Anna; Kim, Yong; Garza, Krishna; Anzures, Humberto; Van Wart, Harold B.

CS Roche Biopharma, Palo Alto, CA, USA; IDA

DI Biocytogen & Medicinal Chemistry Letters (2000), 13(2), 2063-2064

DOI: 10.1021/1000-091X

PI Elsevier Science B.V.

PI Journal

LA English

AB CASREACT 140-77055

AB A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in acute animal models, and pharmacokinetic data are discussed.


IT 200007-21-8

RE PAC (Pharmacological activity); PEP (Pharmacokinetics); PEP (Preclinical); SPN (Synthetic preparation); SPN (Synthesis); SPN (Therapeutic use); SPN (Biological study); SPN (Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs)

IN 200007-21-8 CAPLUS

ON 2-Piperazinecarboxamide, 4-[[4-(4-fluorophenyl)-3,6-dihydro-1,2H-pyridin-3-ylidene]N-hydroxy-N,1'-dimethyl-], US- CA INDEX NAME


Absolute stereochemistry



IN 200007-21-8 CAPLUS

ON 2-Piperazinecarboxamide, 1-[[4-(4-fluorophenyl)-3,6-dihydro-1,2H-pyridin-3-ylidene]N-hydroxy-N,2,2,3-tetrafluoroethyl-], US- CA INDEX NAME

Absolute stereochemistry



IN 200007-21-8 CAPLUS

ON 2-Piperazinecarboxamide, 4-[[4-(4-fluorophenyl)-3,6-dihydro-1,2H-pyridin-3-ylidene]N-hydroxy-N,2,2,3-tetrafluoroethyl-], US- CA INDEX NAME

Absolute stereochemistry



L9 ANKER 8 OF 17 CAPLUS OMPRISET 2009 ACS on STN

AN 2000-039109 CAPLUS

IN 139-32229

TI Synthesis and biological activity of piperazine-based dual MMP-13 and TNF- α converting enzyme inhibitors

AI Letovic, Michael A.; Barbetta, John T.; Certe, Thomas J.; Hardick, Joel S.; Liras, Jennifer; Lopez-Murrow, Lori L.; Mitchell, Peter G.; Roe, Mark C.; Warren, Lisa K.; Dow, Sheri L.; Elm, Ethan J.; Switzer, Francis J.; Vaughn, Marilee L.; Yu, Chul H.

CS Orion Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA

DI Biocytogen & Medicinal Chemistry Letters (2000), 13(10), 3242-3246

DOI: 10.1021/1000-091X

PI Elsevier Science B.V.

PI Journal

LA English

AB CASREACT 139-32229

AB A series of novel MMP-13 and TNF- α converting enzyme inhibitors based on piperazine-2-carboxamide acid scaffolds are described. The TACE, MMP-1, and MMP-13 activity of these inhibitors as well as the effect of substitution of the piperazine nitrogen and the 2-1' benzyloxy tailpiece is discussed. Moderate in vivo activity is observed with several members of this group.

IT 600016-06-3P 600016-07-3P 600016-08-3P

600016-09-3P 600016-10-3P 600016-11-3P

600016-12-3P 600016-13-3P 600016-14-3P

600016-15-3P 600016-16-3P 600016-17-3P

600016-18-3P 600016-19-3P 600016-20-3P

600016-21-3P 600016-22-3P 600016-23-3P

600016-24-3P 600016-25-3P 600016-26-3P

600016-27-3P 600016-28-3P 600016-29-3P

600016-30-3P 600016-31-3P 600016-32-3P

600016-33-3P 600016-34-3P 600016-35-3P

600016-36-3P 600016-37-3P 600016-38-3P

600016-39-3P 600016-40-3P 600016-41-3P

600016-42-3P 600016-43-3P 600016-44-3P

600016-45-3P 600016-46-3P 600016-47-3P

600016-48-3P 600016-49-3P 600016-50-3P

600016-51-3P 600016-52-3P 600016-53-3P

600016-54-3P 600016-55-3P 600016-56-3P

600016-57-3P 600016-58-3P 600016-59-3P

600016-60-3P 600016-61-3P 600016-62-3P


600016-63-3P 600016-64-3P 600016-65-3P

600016-66-3P 600016-67-3P 600016-68-3P

600016-69-3P 600016-70-3P 600016-71-3P


600016-72-3P 600016-73-3P 600016-74-3P

19 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RW 600816-08-0 CAP103
 CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-3-methyl-1-[[4-[(2-methylphenyl)methoxy]phenyl]sulfonyl]-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 009616-99-1 CAPLUS
 CN 2-Piperazinecarboxamide, 4-acetyl-)-[4-[(2-ethylphenyl)methoxy]phenyl)sulfonyl]-N-hydroxy-3-methyl-, (3R,3S)- (CA
 INDEX NAME)

Absolute stereochemistry




RN 600617-00-7 CAPLUS
CN 2-Piperazinecarboxanide, 4-acetyl-1-[[4-[(3,5-

L9 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RD 009617-00-0 CAPLUS
CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-3-methyl-1-[[4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]sulfonyl]-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry




RN 600817-04-1 CAPLUS
CN 2-Piperazinecarboxamide, 6-acetyl-N-hydroxy-1-[[4-(4-
180041011aylmethoxy)phenyl]sulfonyl]-3-methyl-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry


[9] ANSWER 8 OF 17 CAPLIS COPYRIGHT 2008 ACS on STN (Continued)
difluorophenyl)methoxy]phenyl]sulfotyl]-N-hydroxy-S-methyl-, (2R,3S)- (CA
INDEX NAME)

Absolute stereochemistry



IN 600617-01-8 CAFLUS
 CN 2-Piperazinecarboxamide, 4-oxo-1-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-3-methyl-, (2R,3S)- (CA


INDEX NAME
Absolute stereochemistry.



IN 600617-02-9 CAPLUS
 CN 2-Piperazinecarboxamide, 4-acetyl-1-[[4-[(5-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl]-N-hydroxy-2-methyl-, (2R,3S)- (CA INDEX NAME)


Absolute stereochemistry

L9 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IN 600917-06-2 CAPJUS
CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-3-methyl-1-[[4-(4-quinolinyl)methoxy]phenyl]sulfonyl-, (2R,3S)- (CA INDEX NAME)


Absolute stereochemistry



IN 600817-06-3 CAPLUS
CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-5-methyl-1-[[4-(2-methyl-5-
peridinyl)methoxy]butyl]sulfonyl-, (2R,3S)- (CA INDEX NAME)


Absolute stereochemistry

LE NUMBER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




IN 600617-09-1 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.




IN 600617-09-6 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.




LE NUMBER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




IN 600617-10-1 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.



IN 600617-10-2 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME


Absolute stereochemistry.



LE NUMBER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


IN 600617-09-6 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.



IN 600617-10-9 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.



IN 600617-11-9 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME


Absolute stereochemistry.



LE NUMBER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


IN 600617-14-5 CAPLUS
CN 2-Fluorobenzoic acid, N-hydroxy-2-methyl-1-[(4-{(2-methylphenyl)methoxy}phenyl)sulfonyl]-4-(4-methylphenyl)sulfonyl]-, CAS 351-61-6 CA INDEX NAME

Absolute stereochemistry.




RE CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


[9] ANSWER TO QP 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)



BY	210015-07-0	CAPLUS
CN	2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-4-[2-(dimethylamino)ethyl]-N-hydroxy- (CA INDEX NAME)	




RXN 210915-39-2 CAPLUS
 CN 2-Piperazinecarboxamide, 4-acetyl-1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210015-42-7 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-[(2-oxo-1,2,3,4-tetrahydropyridin-5-yl)carbamoyl]- (CA INDEX NAME)


L9 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



BN 310916-46-1 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-]piperidinyl]sulfonyl]-4-formyl-N-hydroxy- (CA INDEX NAME)



RN 210015-47-2 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-[(5-oxo-2-oxopiperidinyl)carboxyl]- (CA INDEX NAME)




IN 210915-49-4 CAPLAS
 CN 2-Piperazinecarboxamide, 4-[[[2S]-2-amino-5-methyl-1-oxobutyl]-1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

OK 1


CSN 216015-49-3
CMF C32 H32 Cl N6 O6 S

Absolute stereochemistry


L9 ANCHOR 10 OF 17 CAPSULE COPYRIGHT 2006 ACS on STM (Continued)



IN 210015-4S-8 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-thienylcarbonyl)- (CA INDEX NAME)




CN 1,3-Piperazinedicarboxamide, 4-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-(2-hydroxy-N-(phenylmethyl)-2-oxo-3-phenylpropan-1-yl)-
 CA INDEX NAME



IN 210015-45-0 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-4-(cyclohexylcarbonyl)-N-hydroxy- (CA INDEX NAME)

L9 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STM (Continued)




Q 2


CEN 76-05-1
CMP C2 H P3 00



IN 210915-50-7 CAPLUS
CN 1,3-Piperazinedicarboxamide, 4-[[4-(4-chlorobenzoyl)-1-
piperidinyl]sulfonyl]-N3-hydroxy-N1-methyl)- (CA INDEX NAME)




IN 210015-51-8 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(1-oxopropyl)- (CA INDEX NAME)



IN 210015-54-1 CAPLIS
ON 1,3-Piperazinedicarboxamide, 4-[[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N(1-hydroxy-N(1-phenyl)- (CA INDEX NAME)


19 ANKER 10 06 17 CAPLUS OMPRIGHT 2006 ACS on STM (Continued)
 IN 210615-06-7 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[[[(2S)-2-amino-3-methyl-3-oxobutyl]-1-[(4-{6-fluoro-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)

Absolute stereochemistry




IN 210615-06-8 CAPLUS
 CN 1,3-Dipiperazinecarboxamide, NO-hydroxy-N,N-dimethyl-4-[[4-{4,5,6,7-tetrafluoro-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-, GHO- (CA INDEX NAME)

Absolute stereochemistry



IN 210615-06-9 CAPLUS
 CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[[4-{6-fluoro-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-N-hydroxy-, GHO- (CA INDEX NAME)

Absolute stereochemistry




IN 210615-06-9 CAPLUS

19 ANKER 10 06 17 CAPLUS OMPRIGHT 2006 ACS on STM (Continued)


IN 210616-00-0 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-{4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(4-morpholinylcarboxyl)-, GHO- (CA INDEX NAME)

Absolute stereochemistry



IN 210616-01-1 CAPLUS
 CN 1,3-Dipiperazinecarboxamide, 4-[[4-{(S)-cyclo-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-N,N'-bis-(1,1-dimethyl-2-pyrrolidinyl)-N-hydroxy-, GHO- (CA INDEX NAME)


Absolute stereochemistry




IN 210616-05-3 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-{4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridinylcarboxyl)-, GHO- (CA INDEX NAME)

Absolute stereochemistry

19 ANKER 10 06 17 CAPLUS OMPRIGHT 2006 ACS on STM (Continued)
 CN 2-Piperazinecarboxamide, 4-[[4-(4-chlorobenzoyl) sulfonyl]-1-[[4-{6-fluoro-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




IN 210616-06-1 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[[4-(4-(dimethylamino)phosphoryl)-1-[[4-{6-fluoro-1H-indol-3-yl})-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IN 210616-06-2 CAPLUS
 CN 1,3-Dipiperazinecarboxamide, 4-[[4-(4-fluorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, GHO- (CA INDEX NAME)

Absolute stereochemistry




IN 210616-00-4 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-4-[[dimethylamino)sulfonyl]-N-hydroxy-, GHO- (CA INDEX NAME)

Absolute stereochemistry




19 ANKER 10 06 17 CAPLUS OMPRIGHT 2006 ACS on STM (Continued)




IN 210616-04-4 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridinylmethyl)-, GHO- (CA INDEX NAME)

Absolute stereochemistry




IN 210616-06-5 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-(S-cyclo-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(4-morpholinylcarboxyl)-, GHO- (CA INDEX NAME)

Absolute stereochemistry



IN 210616-06-6 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl)-N-hydroxy-4-(2,2,2-trifluoroethyl)-, GHO- (CA INDEX NAME)




L9 ANKER 10 OF 17 CAPLUS OMPKIGHT 2006 ACS on STM (Continued)

IN 21061E-6I-7 CAPLUS

CN 2-Fluorobenzoic acid, 4-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-3-(hydroxymethyl)-, (S)- (CA INDEX NAME)


Absolute stereochemistry.



IN 21061E-14-6 CAPLUS


CN 2-Fluorobenzoic acid, 1-[[4-(6-fluoro-3H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(pyrazinylcarbonyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



IN 21061E-16-8 CAPLUS

CN 2-Fluorobenzoic acid, 4-[[4-(6-chloro-1-[[2-(trifluoromethyl)ethyl]sulfonyl]-3H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-(hydroxymethyl)-, phenylmethyl ester (CA INDEX NAME)




IN 21061E-17-9 CAPLUS

L9 ANKER 10 OF 17 CAPLUS OMPKIGHT 2006 ACS on STM (Continued)


IN 21061E-2D-7 CAPLUS

CN 1,3-Fluorobenzoic acid, 4-[[4-(4-chlorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4,6-dimethyl- (CA INDEX NAME)




IN 21061E-6E-7 CAPLUS

CN 2-Fluorobenzoic acid, 4-[[4-(4-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-3-(hydroxymethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



IN 21061E-70-4 CAPLUS


CN 1,3-Fluorobenzoic acid, 4-[[4-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4,6-dimethyl- (CA INDEX NAME)



IN 21061E-71-5 CAPLUS

CN 1,3-Fluorobenzoic acid, 4-[[4-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



L9 ANKER 10 OF 17 CAPLUS OMPKIGHT 2006 ACS on STM (Continued)


CN

2-Fluorobenzoic acid, 4-[[4-(6-fluoro-1-[[2-(trifluoromethyl)ethyl]sulfonyl]-3H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-(hydroxymethyl)-, phenylmethyl ester (CA INDEX NAME)




IN 21061E-6I-4 CAPLUS

CN 2-Fluorobenzoic acid, 4-[[4-(4-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-3-(hydroxymethyl)-, phenylmethyl ester (CA INDEX NAME)




IN 21061E-6E-5 CAPLUS

CN 2-Fluorobenzoic acid, 4-acetyl-1-[[4-(4-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IN 21061E-64-6 CAPLUS


CN 1,3-Fluorobenzoic acid, 4-[[4-(4-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4,6-dimethyl- (CA INDEX NAME)



L9 ANKER 10 OF 17 CAPLUS OMPKIGHT 2006 ACS on STM (Continued)


IN 21061E-7D-7 CAPLUS

CN 1,3-Fluorobenzoic acid, 4-[[4-(4-chlorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4,6-dimethyl- (CA INDEX NAME)




IN 21061E-7E-9 CAPLUS

CN 1,3-Fluorobenzoic acid, 4-[[4-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




IN 21061E-7T-3 CAPLUS

CN 2-Fluorobenzoic acid, 4-[[4-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




IN 21061E-7B-3 CAPLUS


CN 2-Fluorobenzoic acid, 1-[[4-(4-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4-(4-morpholinylcarbonyl)- (CA INDEX NAME)



19 ANDER 10 06 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 IN 216616-19-3 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)-3,6-dihydro-2H-pyridin-5-ylidene]methyl]-N-hydroxy-4-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




IN 216616-99-6 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[[2-(dimethylamino)ethylamino]-1-[[4-(4-chlorophenyl)-3,6-dihydro-2H-pyridin-5-ylidene]methyl]-N-hydroxy- (CA INDEX NAME)



IN 216617-17-2 CAPLUS
 CN 1,3-Bis[2-(dimethylamino)ethylamino], 4-[[4-(4-chlorophenyl)-1-piperidin-3-ylidene]methyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



IN 416946-37-2 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[4-(5-phenyl-1H-imidazol-2-yl)-1-piperidin-3-ylidene]methyl]-N-hydroxy-4-(dimethylamino)ethyl- N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry

19 ANDER 10 06 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



IN 416946-38-5 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[[4-(5-phenyl-1H-imidazol-2-yl)-1-piperidin-3-ylidene]methyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



IT 216617-47-50
 RE: ICT (Inventor); STM (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

IT Preparation of sulfonamides as metalloprotease inhibitors

IN 216617-47-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[4-(5-phenyl-1-[2-(2-methylvinyl)ethylamino]methyl]-1H-imidazol-2-yl)-1-piperidin-3-ylidene]methyl]-N-hydroxyamino)carboxyl-, phenylmethyl ester (CA INDEX NAME)



RE: CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

19 ANDER 10 06 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)

19 ANDER 11 06 17 CAPLUS COPYRIGHT 2006 ACS on STM

IN 2001-167695 CAPLUS
 IN 154-207559
 IT Preparation of N-(5-benzoylbenzimidazolylmethyl)piperidine and piperazine derivatives as selective inhibitors of angiotensin II in osteoarthritis treatment
 IN Rev. Mark Carl; Letarovic, Michael A.; Hawkins, Joel M.
 IN Pfizer Products Inc., USA
 IN Bur. Pat. Appl., 65 pp.



CONV: EP/CN

IP Patent

LA Ref/ab

PAN: CH


PI	EP	1461137	A1	2000/0747	EP	2000-200746		2000/0808
	E:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, SI, PT, TR, US, UZ, VN	PT	86				
	CA	2315481	A1	2000/0212	CA	2000-2315481		2000/0810
	JP	2001114903	A	2000/0424	JP	2000-243339		2000/0810
	JP	2000/04000	A	2000/0212	JP	2002-210877		2000/0810
	MX	2000/078781	A	2000/0725	MX	2000-PI/781		2000/0811
	BR	2000/04000	A	2000/0424	BR	2000-2040		2000/0814
	JP	2000/181396	A	2000/0617	JP	2000-27498		2000/0814
	US	2000/071997	A1	2000/0613	US	2000-120076		2000/0815
	US	1052043	B2	2000/0618				
FR/AT	US	1299-1464/97	P	1299/0613				
	JP	2000-243139	A5	2000/0610				
	US	2000-430613	A5	2000/0610				
	OE	MARKET 154-207559						
	GI							



AB The title compounds (I) or therapeutically acceptable salts thereof [wherein X is carbon or nitrogen; R1 and R2 are independently selected from the group consisting of hydrogen, hydroxyl, and Me, wherein at least one of R1 and R2 is methyl; R3 and R4 are independently selected from the group consisting of hydrogen, hydroxyl, and Me, or R3 and R4 may be taken together to form a carbonyl group; and R5 and R6 are independently substituted on the ortho, meta, or para positions and are independently selected from the group consisting of hydrogen, halogen, cyano, Me, and ethyl, with the proviso that when X is carbon, then R3 and R4 are both hydrogen and at least one of R1, R2, R3, and R4 is hydrogen, when X is

- 19 NUMBER 11 OF IT CAPLUS OFFRIGHT 2006 ACS on STM (Continued)
- carbon and R₁ is naphthalenyl, then at least one of R₁, R₂, and R₃ is not hydrogen, when R₁ is naphthalenyl, then R₂ is not present and R₃ is a hydroxyl or a group of the formula wherein, Y is -CH₂-NH₂ or -NH-CH₂ and when X is an amine and R₃ is H, then R₂ and R₃ are taken together to form a carbonyl group [e.g., II] are used. A method of treatment for osteoarthritis, rheumatic inhibitors of aggrecan that demonstrate ED₅₀ of less than 20 μM and demonstrate differential potency against matrix metalloproteinases (MMPs) and 4 diastereoisomers of metalloproteinases (MMPs or metalloproteinases). These compounds are useful for the treatment of a condition selected from the group consisting of osteoarthritis, joint injury, reactive arthritis, acute proinflammatory arthritis (psoriasis), psoriatic arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, eczema, allergic reactions, allergic contact hypersensitivity, cancer, tissue laceration, retinopathy, periodontal disease, endometriosis, bullous, osteoporosis, loosening of artificial joint implants, atherosclerosis, acute coronary, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative disorders, autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, neuronal necrosis, pain, central amyloid angiopathy, osteoporosis or cognition enhancement, osteoporosis, lateral scoliosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, cerebral swelling, septicemia, ALKS, or sepsis or septic shock, in a mammal. It showed ED₅₀ of (10, 10³ to 10⁶), 1,000, and 100 μM against aggrecanase, MMP-13, MMP-1, and MMP-2, resp.
- IT 200600-98-2 200600-99-3 200600-99-4 200600-99-5 200600-99-6 200600-99-7 200600-99-8 200600-99-9 200600-10-0 200600-10-1 200600-10-2 200600-10-3 200600-10-4 200600-10-5 200600-10-6 200600-10-7 200600-10-8 200600-10-9 200600-10-10 200600-10-11 200600-10-12 200600-10-13 200600-10-14 200600-10-15 200600-10-16 200600-10-17 200600-10-18 200600-10-19 200600-10-20 200600-10-21 200600-10-22 200600-10-23 200600-10-24 200600-10-25 200600-10-26 200600-10-27 200600-10-28 200600-10-29 200600-10-30 200600-10-31 200600-10-32 200600-10-33 200600-10-34 200600-10-35 200600-10-36 200600-10-37 200600-10-38 200600-10-39 200600-10-40 200600-10-41 200600-10-42 200600-10-43 200600-10-44 200600-10-45 200600-10-46 200600-10-47 200600-10-48 200600-10-49 200600-10-50 200600-10-51 200600-10-52 200600-10-53 200600-10-54 200600-10-55 200600-10-56 200600-10-57 200600-10-58 200600-10-59 200600-10-60 200600-10-61 200600-10-62 200600-10-63 200600-10-64 200600-10-65 200600-10-66 200600-10-67 200600-10-68 200600-10-69 200600-10-70 200600-10-71 200600-10-72 200600-10-73 200600-10-74 200600-10-75 200600-10-76 200600-10-77 200600-10-78 200600-10-79 200600-10-80 200600-10-81 200600-10-82 200600-10-83 200600-10-84 200600-10-85 200600-10-86 200600-10-87 200600-10-88 200600-10-89 200600-10-90 200600-10-91 200600-10-92 200600-10-93 200600-10-94 200600-10-95 200600-10-96 200600-10-97 200600-10-98 200600-10-99 200600-10-100 200600-10-101 200600-10-102 200600-10-103 200600-10-104 200600-10-105 200600-10-106 200600-10-107 200600-10-108 200600-10-109 200600-10-110 200600-10-111 200600-10-112 200600-10-113 200600-10-114 200600-10-115 200600-10-116 200600-10-117 200600-10-118 200600-10-119 200600-10-120 200600-10-121 200600-10-122 200600-10-123 200600-10-124 200600-10-125 200600-10-126 200600-10-127 200600-10-128 200600-10-129 200600-10-130 200600-10-131 200600-10-132 200600-10-133 200600-10-134 200600-10-135 200600-10-136 200600-10-137 200600-10-138 200600-10-139 200600-10-140 200600-10-141 200600-10-142 200600-10-143 200600-10-144 200600-10-145 200600-10-146 200600-10-147 200600-10-148 200600-10-149 200600-10-150 200600-10-151 200600-10-152 200600-10-153 200600-10-154 200600-10-155 200600-10-156 200600-10-157 200600-10-158 200600-10-159 200600-10-160 200600-10-161 200600-10-162 200600-10-163 200600-10-164 200600-10-165 200600-10-166 200600-10-167 200600-10-168 200600-10-169 200600-10-170 200600-10-171 200600-10-172 200600-10-173 200600-10-174 200600-10-175 200600-10-176 200600-10-177 200600-10-178 200600-10-179 200600-10-180 200600-10-181 200600-10-182 200600-10-183 200600-10-184 200600-10-185 200600-10-186 200600-10-187 200600-10-188 200600-10-189 200600-10-190 200600-10-191 200600-10-192 200600-10-193 200600-10-194 200600-10-195 200600-10-196 200600-10-197 200600-10-198 200600-10-199 200600-10-200 200600-10-201 200600-10-202 200600-10-203 200600-10-204 200600-10-205 200600-10-206 200600-10-207 200600-10-208 200600-10-209 200600-10-210 200600-10-211 200600-10-212 200600-10-213 200600-10-214 200600-10-215 200600-10-216 200600-10-217 200600-10-218 200600-10-219 200600-10-220 200600-10-221 200600-10-222 200600-10-223 200600-10-224 200600-10-225 200600-10-226 200600-10-227 200600-10-228 200600-10-229 200600-10-230 200600-10-231 200600-10-232 200600-10-233 200600-10-234 200600-10-235 200600-10-236 200600-10-237 200600-10-238 200600-10-239 200600-10-240 200600-10-241 200600-10-242 200600-10-243 200600-10-244 200600-10-245 200600-10-246 200600-10-247 200600-10-248 200600-10-249 200600-10-250 200600-10-251 200600-10-252 200600-10-253 200600-10-254 200600-10-255 200600-10-256 200600-10-257 200600-10-258 200600-10-259 200600-10-260 200600-10-261 200600-10-262 200600-10-263 200600-10-264 200600-10-265 200600-10-266 200600-10-267 200600-10-268 200600-10-269 200600-10-270 200600-10-271 200600-10-272 200600-10-273 200600-10-274 200600-10-275 200600-10-276 200600-10-277 200600-10-278 200600-10-279 200600-10-280 200600-10-281 200600-10-282 200600-10-283 200600-10-284 200600-10-285 200600-10-286 200600-10-287 200600-10-288 200600-10-289 200600-10-290 200600-10-291 200600-10-292 200600-10-293 200600-10-294 200600-10-295 200600-10-296 200600-10-297 200600-10-298 200600-10-299 200600-10-300 200600-10-301 200600-10-302 200600-10-303 200600-10-304 200600-10-305 200600-10-306 200600-10-307 200600-10-308 200600-10-309 200600-10-310 200600-10-311 200600-10-312 200600-10-313 200600-10-314 200600-10-315 200600-10-316 200600-10-317 200600-10-318 200600-10-319 200600-10-320 200600-10-321 200600-10-322 200600-10-323 200600-10-324 200600-10-325 200600-10-326 200600-10-327 200600-10-328 200600-10-329 200600-10-330 200600-10-331 200600-10-332 200600-10-333 200600-10-334 200600-10-335 200600-10-336 200600-10-337 200600-10-338 200600-10-339 200600-10-340 200600-10-341 200600-10-342 200600-10-343 200600-10-344 200600-10-345 200600-10-346 200600-10-347 200600-10-348 200600-10-349 200600-10-350 200600-10-351 200600-10-352 200600-10-353 200600-10-354 200600-10-355 200600-10-356 200600-10-357 200600-10-358 200600-10-359 200600-10-360 200600-10-361 200600-10-362 200600-10-363 200600-10-364 200600-10-365 200600-10-366 200600-10-367 200600-10-368 200600-10-369 200600-10-370 200600-10-371 200600-10-372 200600-10-373 200600-10-374 200600-10-375 200600-10-376 200600-10-377 200600-10-378 200600-10-379 200600-10-380 200600-10-381 200600-10-382 200600-10-383 200600-10-384 200600-10-385 200600-10-386 200600-10-387 200600-10-388 200600-10-389 200600-10-390 200600-10-391 200600-10-392 200600-10-393 200600-10-394 200600-10-395 200600-10-396 200600-10-397 200600-10-398 200600-10-399 200600-10-400 200600-10-401 200600-10-402 200600-10-403 200600-10-404 200600-10-405 200600-10-406 200600-10-407 200600-10-408 200600-10-409 200600-10-410 200600-10-411 200600-10-412 200600-10-413 200600-10-414 200600-10-415 200600-10-416 200600-10-417 200600-10-418 200600-10-419 200600-10-420 200600-10-421 200600-10-422 200600-10-423 200600-10-424 200600-10-425 200600-10-426 200600-10-427 200600-10-428 200600-10-429 200600-10-430 200600-10-431 200600-10-432 200600-10-433 200600-10-434 200600-10-435 200600-10-436 200600-10-437 200600-10-438 200600-10-439 200600-10-440 200600-10-441 200600-10-442 200600-10-443 200600-10-444 200600-10-445 200600-10-446 200600-10-447 200600-10-448 200600-10-449 200600-10-450 200600-10-451 200600-10-452 200600-10-453 200600-10-454 200600-10-455 200600-10-456 200600-10-457 200600-10-458 200600-10-459 200600-10-460 200600-10-461 200600-10-462 200600-10-463 200600-10-464 200600-10-465 200600-10-466 200600-10-467 200600-10-468 200600-10-469 200600-10-470 200600-10-471 200600-10-472 200600-10-473 200600-10-474 200600-10-475 200600-10-476 200600-10-477 200600-10-478 200600-10-479 200600-10-480 200600-10-481 200600-10-482 200600-10-483 200600-10-484 200600-10-485 200600-10-486 200600-10-487 200600-10-488 200600-10-489 200600-10-490 200600-10-491 200600-10-492 200600-10-493 200600-10-494 200600-10-495 200600-10-496 200600-10-497 200600-10-498 200600-10-499 200600-10-500 200600-10-501 200600-10-502 200600-10-503 200600-10-504 200600-10-505 200600-10-506 200600-10-507 200600-10-508 200600-10-509 200600-10-510 200600-10-511 200600-10-512 200600-10-513 200600-10-514 200600-10-515 200600-10-516 200600-10-517 200600-10-518 200600-10-519 200600-10-520 200600-10-521 200600-10-522 200600-10-523 200600-10-524 200600-10-525 200600-10-526 200600-10-527 200600-10-528 200600-10-529 200600-10-530 200600-10-531 200600-10-532 200600-10-533 200600-10-534 200600-10-535 200600-10-536 200600-10-537 200600-10-538 200600-10-539 200600-10-540 200600-10-541 200600-10-542 200600-10-543 200600-10-544 200600-10-545 200600-10-546 200600-10-547 200600-10-548 200600-10-549 200600-10-550 200600-10-551 200600-10-552 200600-10-553 200600-10-554 200600-10-555 200600-10-556 200600-10-557 200600-10-558 200600-10-559 200600-10-560 200600-10-561 200600-10-562 200600-10-563 200600-10-564 200600-10-565 200600-10-566 200600-10-567 200600-10-568 200600-10-569 200600-10-570 200600-10-571 200600-10-572 200600-10-573 200600-10-574 200600-10-575 200600-10-576 200600-10-577 200600-10-578 200600-10-579 200600-10-580 200600-10-581 200600-10-582 200600-10-583 200600-10-584 200600-10-585 200600-10-586 200600-10-587 200600-10-588 200600-10-589 200600-10-590 200600-10-591 200600-10-592 200600-10-593 200600-10-594 200600-10-595 200600-10-596 200600-10-597 200600-10-598 200600-10-599 200600-10-600 200600-10-601 200600-10-602 200600-10-603 200600-10-604 200600-10-605 200600-10-606 200600-10-607 200600-10-608 200600-10-609 200600-10-610 200600-10-611 200600-10-612 200600-10-613 200600-10-614 200600-10-615 200600-10-616 200600-10-617 200600-10-618 200600-10-619 200600-10-620 200600-10-621 200600-10-622 200600-10-623 200600-10-624 200600-10-625 200600-10-626 200600-10-627 200600-10-628 200600-10-629 200600-10-630 200600-10-631 200600-10-632 200600-10-633 200600-10-634 200600-10-635 200600-10-636 200600-10-637 200600-10-638 200600-10-639 200600-10-640 200600-10-641 200600-10-642 200600-10-643 200600-10-644 200600-10-645 200600-10-646 200600-10-647 200600-10-648 200600-10-649 200600-10-650 200600-10-651 200600-10-652 200600-10-653 200600-10-654 200600-10-655 200600-10-656 200600-10-657 200600-10-658 200600-10-659 200600-10-660 200600-10-661 200600-10-662 200600-10-663 200600-10-664 200600-10-665 200600-10-666 200600-10-667 200600-10-668 200600-10-669 200600-10-670 200600-10-671 200600-10-672 200600-10-673 200600-10-674 200600-10-675 200600-10-676 200600-10-677 200600-10-678 200600-10-679 200600-10-680 200600-10-681 200600-10-682 200600-10-683 200600-10-684 200600-10-685 200600-10-686 200600-10-687 200600-10-688 200600-10-689 200600-10-690 200600-10-691 200600-10-692 200600-10-693 200600-10-694 200600-10-695 200600-10-696 200600-10-697 200600-10-698 200600-10-699 200600-10-700 200600-10-701 200600-10-702 200600-10-703 200600-10-704 200600-10-705 200600-10-706 200600-10-707 200600-10-708 200600-10-709 200600-10-710 200600-10-711 200600-10-712 200600-10-713 200600-10-714 200600-10-715 200600-10-716 200600-10-717 200600-10-718 200600-10-719 200600-10-720 200600-10-721 200600-10-722 200600-10-723 200600-10-724 200600-10-725 200600-10-726 200600-10-727 200600-10-728 200600-10-729 200600-10-730 200600-10-731 200600-10-732 200600-10-733 200600-10-734 200600-10-735 200600-10-736 200600-10-737 200600-10-738 200600-10-739 200600-10-740 200600-10-741 200600-10-742 200600-10-743 200600-10-744 200600-10-745 200600-10-746 200600-10-747 200600-10-748 200600-10-749 200600-10-750 200600-10-751 200600-10-752 200600-10-753 200600-10-754 200600-10-755 200600-10-756 200600-10-757 200600-10-758 200600-10-759 200600-10-760 200600-10-761 200600-10-762 200600-10-763 200600-10-764 200600-10-765 200600-10-766 200600-10-767 200600-10-768 200600-10-769 200600-10-770 200600-10-771 200600-10-772 200600-10-773 200600-10-774 200600-10-775 200600-10-776 200600-10-777 200600-10-778 200600-10-779 200600-10-780 200600-10-781 200600-10-782 200600-10-783 200600-10-784 200600-10-785 200600-10-786 200600-10-787 200600-10-788 200600-10-789 200600-10-790 200600-10-791 200600-10-792 200600-10-793 200600-10-794 200600-10-795 200600-10-796 200600-10-797 200600-10-798 200600-10-799 200600-10-800 200600-10-801 200600-10-802 200600-10-803 200600-10-804 200600-10-805 200600-10-806 200600-10-807 200600-10-808 200600-10-809 200600-10-810 200600-10-811 200600-10-812 200600-10-813 200600-10-814 200600-10-815 200600-10-816 200600-10-817 200600-10-818 200600-10-819 200600-10-820 200600-10-821 200600-10-822 200600-10-823 200600-10-824 200600-10-825 200600-10-826 200600-10-827 200600-10-828 200600-10-829 200600-10-830 200600-10-831 200600-10-

L9 ANKER 11 0F 17 CAPLIS OFFRIGHT 2006 ACS ON STN (Continued)

RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FOOTNOT

L9 ANKER 12 0F 17 CAPLIS OFFRIGHT 2006 ACS ON STN

AN 2000 R23554 CAPLIS

IN 174 0300

TI Preparation of 1-phenylpiperazine-2-hydroxamate as metalloproteinase

inhibitors

IN Zook, Scott E.; Barnum, Raymond, Jr.; Deason, Michael E.; Bender, Steven

L.; Beland, Michael J.

PA Acunon Pharmaceuticals, Inc., USA

SP U.S., 40 U.S. Cont.-part of U.S. 5,753,635.

DT 000000 USNAM

PT Patent

LA English

PAN CNT 1

PI	US 6153357	A	2000/11/18	US 1998-11971	1998/06/29
	W9 92/08241	A	1992/06/12	W9 1991-01/0029	1991/10/01
	F	AK, AT, AU, BE, BR, CA, CH, CN, DE, DK, ES, FI, FR, GB, GR, HU, IL, IN, JP, KR, MA, NL, NO, NZ, PL, PT, RU, SE, SG, SI, SK, TH, TR, TW, UA, US, VE, VN			
	EP 6170363	A	1998/06/19	US 1996-70175	1996/12/06
	US 6100664	RI	2000/01/10	US 2000-675335	2000/06/29
	US 2000/01/06/06	AI	2000/01/10	US 2000-298843	2002/11/18
	US 6145752	E	2000/06/29		
FRAT	US 1996-41490	F	1996/12/06		
	W9 1996-01/0029	E	1996/12/06		
	US 1996-199715	A	1996/12/06		
	US 1996-669704	A	1996/12/06		
	US 1996-11971	AD	1996/06/29		
	US 2000-675335	A	2000/06/29		

05 MARPAT 134-0960


AB 421150002(US20000000) [1: 8 - (hetero)aryl; R² = atoms to complete a heterocyclic ring; Z = O or S; Z1 = 1,4-thienyl] were screened. Thus, (S)-N-methyl-1-[(4-(4-chlorophenyl)phenylsulfonyl)-4-(4-hydroxy-4-methylpentan-2-one)-2-yl]piperazine-2-carboxamide (a p. 94, 67), prepared from (S)-piperazine-2-carboxylic acid in a step, demonstrated 71 % inhibition of lung metastases in a female mouse Lewis lung carcinoma model at 50 mg/kg.

IT 192529-44-1P 192529-52-5P 192529-79-6P
AC, BC: Biological activity as expected, except adverse; BEU (Biological study, unclassified); BCT (Biochemical); PPM (Synthetic preparation); THU (Therapeutic use); BMM (Biological study); PRP (Preparation); MGT (Metabolite or metabolite); MGS (Metabolite).
Preparation of heterocyclic metalloproteinase-inhibitor antitumor agents and antitumor agents

IN 192529-44-1 CAPLIS

ON 1,3-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)phenylsulfonyl]-3-[(hydroxymethyl)carboxyl]-1,1-dimethylethyl ester (CA INDEX NAME)


L9 ANKER 12 0F 17 CAPLIS OFFRIGHT 2006 ACS ON STN (Continued)



RE 192529-52-5 CAPLIS

ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenylsulfonyl]-4-hydroxy-4-methylpentan-2-yl]- (CA INDEX NAME)


Absolute stereochemistry



RE 192529-79-6 CAPLIS

ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenylsulfonyl]-4-hydroxy-4-methylpentan-2-yl]- (CA INDEX NAME)

Absolute stereochemistry



IT 192529-45-6P 192529-46-7P 192529-47-8P

192529-48-9P 192529-49-0P 192529-50-1P

192529-40-9P 192529-41-0P 192529-42-1P

192529-43-2P 192529-44-3P 192529-45-4P

192529-46-5P 192529-47-6P 192529-48-7P

192529-49-8P 192529-50-9P 192529-51-0P


192529-52-1P 192529-53-2P

AC, BC: Biological activity as expected, except adverse; BEU (Biological study, unclassified); PPM (Synthetic preparation); THU (Therapeutic use); BMM (Biological study); PRP (Preparation); MGT (Metabolite or metabolite); MGS (Metabolite).
Preparation of heterocyclic metalloproteinase-inhibitor antitumor agents and antitumor agents

RE 192529-45-6 CAPLIS


ON 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenylsulfonyl]-4-hydroxy-4-methylpentan-2-yl]- (CA INDEX NAME)

L9 ANKER 12 0F 17 CAPLIS OFFRIGHT 2006 ACS ON STN (Continued)



RE 192529-46-7 CAPLIS

ON 1,3-Piperazinecarboxamide, 4-[[4-(4-chlorophenyl)phenylsulfonyl]-4-hydroxy-4-methyl]- (CA INDEX NAME)



RE 192529-47-8 CAPLIS


ON 2-Piperazinecarboxamide, 4-[[4-(4-chlorophenyl)phenylsulfonyl]-4-hydroxy-4-methyl]- (CA INDEX NAME)



RE 192529-49-0 CAPLIS

ON 1,3-Piperazinecarboxylic acid, 4-[[4-(4-chlorophenyl)phenylsulfonyl]-3-[(hydroxymethyl)carboxyl]-1,1-dimethylethyl ester, (S)- (CA INDEX NAME)


Absolute stereochemistry



RE 192529-50-1 CAPLIS


19 ANKER 12 06 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-
 5,5-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-11-4 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-
 5-methyl-, hydrochloride (1:1), (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-49-6 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-fluorophenyl)phenyl]sulfonyl]-N-hydroxy-
 5,5-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-62-0 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-
 5,5-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-73-0 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-fluorophenyl)thiophenyl]sulfonyl]-N-
 hydroxy-5,5-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-74-5 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-
 hydroxy-5,5-dimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-75-2 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-fluorophenyl)thiophenyl]sulfonyl]-N-
 hydroxy-5,5,4-trimethyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry




BN 19C329-76-5 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-
 hydroxy-5,5,4-trimethyl-, (S)- (CA INDEX NAME)


19 ANKER 12 06 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)




Absolute stereochemistry



Absolute stereochemistry




Absolute stereochemistry




Absolute stereochemistry




Absolute stereochemistry



Absolute stereochemistry



Absolute stereochemistry




Absolute stereochemistry




Absolute stereochemistry

19 ANEXER 13 OF 17 CAPLUS OMPRIGET 2006 ACS on STM (Continued)
 RN 190529-44-6 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-(4-hydroxyphenyl)carbamate (CA INDEX NAME)



RN 190529-46-2 CAPLUS
 CN 1,3-bis(2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl)-N-(4-hydroxyphenyl)carbamate, 4-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-(4-hydroxyphenyl)carbamate (CA INDEX NAME)



RN 190529-47-6 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-(4-phenoxyphenyl)carbamate, 4-acetyl-N-hydroxy-1-[[4-(4-bromophenyl)phenyl]sulfonyl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)




RN 190529-49-5 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)

19 ANEXER 13 OF 17 CAPLUS OMPRIGET 2006 ACS on STM (Continued)




RN 190529-50-9 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)



RN 190529-51-9 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RN 190529-52-2 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)

Absolute stereochemistry


19 ANEXER 13 OF 17 CAPLUS OMPRIGET 2006 ACS on STM (Continued)




RN 190529-59-9 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)



RN 190796-08-2 CAPLUS
 CN 1-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)




RN 190796-09-3 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)



RN 190796-11-7 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)




19 ANEXER 13 OF 17 CAPLUS OMPRIGET 2006 ACS on STM (Continued)



● [C@H]

RN 190529-53-4 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



● [C@H]


RN 190529-53-4 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)

Absolute stereochemistry




RN 190529-54-6 CAPLUS
 CN 2-[2-fluoro-4-oxo-1,2,3,4-tetrahydro-1H-benzothiazol-5-yl]-N-hydroxy-2,3-dimethyl-2'-oxo-1,1'-biphenyl-4'-carboxamide (CA INDEX NAME)

L9 ANKER 14 06 17 CAPLIC OMFXRIGT 2006 ACS on STN (Continued)



BN 210015-42-1 CAPLIC
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridyl)carboxylate- (CA INDEX NAME)




BN 210015-43-8 CAPLIC
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridyl)carboxylate- (CA INDEX NAME)



BN 210015-44-9 CAPLIC
CN 1,3-Piperazinecarboxamide, 4-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-N-(phenylmethyl)- (CA INDEX NAME)

L9 ANKER 14 06 17 CAPLIC OMFXRIGT 2006 ACS on STN (Continued)




BN 210015-49-4 CAPLIC
CN 2-Piperazinecarboxamide, 4-[[2S]-2-amino-2-methyl-1-oxobutyl]-1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CN 1

CN 210015-48-0
CN 210015-48-0

Absolute stereochemistry.




CN 2

CN 16-05-1
CN 16-05-1




BN 210015-50-7 CAPLIC
CN 1,3-Piperazinecarboxamide, 4-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-N-methyl- (CA INDEX NAME)


L9 ANKER 14 06 17 CAPLIC OMFXRIGT 2006 ACS on STN (Continued)



BN 210015-45-0 CAPLIC
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-4-formyl-N-hydroxy- (CA INDEX NAME)




BN 210015-46-1 CAPLIC
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-4-formyl-N-hydroxy- (CA INDEX NAME)




BN 210015-47-3 CAPLIC
CN 2-Piperazinecarboxamide, 1-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-oxo-2-pyrrolidinyl)carboxylate- (CA INDEX NAME)


L9 ANKER 14 06 17 CAPLIC OMFXRIGT 2006 ACS on STN (Continued)




BN 210015-51-8 CAPLIC
CN 2-Piperazinecarboxamide, 4-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(1-oxopropyl)- (CA INDEX NAME)



BN 210015-54-1 CAPLIC
CN 1,3-Piperazinecarboxamide, 4-[[4-(4-chlorobenzoyl)-1-piperidinyl]sulfonyl]-N-hydroxy-N-phenyl- (CA INDEX NAME)




BN 210015-59-6 CAPLIC
CN 2-Piperazinecarboxylic acid, 4-[[4-(4-fluoro-3H-indol-3-yl)-1-piperidinyl]sulfonyl]-2-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




BN 210015-60-9 CAPLIC
CN 1-Piperazinecarboxylic acid, 4-[[4-(4-chloro-3H-indol-3-yl)-1-piperidinyl]sulfonyl]-2-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)


L9 ANWER 14 0F 17 CAPLUS OMPYRIGHT 2006 ACS on STM (Continued)



IN 210015-41-0 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)



IN 210015-42-1 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-47-4 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)


CM 1
CIN 210015-48-5
COP 112 024 01 NE 05

L9 ANWER 14 0F 17 CAPLUS OMPYRIGHT 2006 ACS on STM (Continued)


Absolute stereochemistry



IN 210015-46-9 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-47-0 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)



IN 210015-48-1 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)

L9 ANWER 14 0F 17 CAPLUS OMPYRIGHT 2006 ACS on STM (Continued)




CM 2


CIN 70 06-1
COP 12 01 02



IN 210015-48-7 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-74-5 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-82-5 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)


L9 ANWER 14 0F 17 CAPLUS OMPYRIGHT 2006 ACS on STM (Continued)



IN 210015-89-2 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-90-5 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)




IN 210015-92-7 CAPLUS
CN 2-[4-chlorobenzoyl]-1-piperidine-3-carboxylic acid, 4-[[4-(6-chlorobenzoyl)-1-piperidinyl]sulfonyl]-1-piperidine-3-carboxylic acid, methyl ester (CA INDEX NAME)

Absolute stereochemistry




19 ANWER 14 0F 17 CAPLIS OMPYX0207 2006 ACS on STN (Continued)
 IN 210915-06-8 CAPLIS
 ON 1,5-Diphenylacetamidoamide, N-(hydroxy-N,N-dimethyl-4-[[4-(4,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 210915-96-9 CAPLIS
 ON 2-Piperazinylacetamidoamide, 4-(cyclopropylmethyl)-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 210915-96-8 CAPLIS
 ON 2-Piperazinylacetamidoamide, 4-[(dimethylamino)sulfonyl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)




IN 210915-96-1 CAPLIS
 ON 2-Piperazinylacetamidoamide, 4-[bis(dimethylamino)phosphoryl]-1-[[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)

19 ANWER 14 0F 17 CAPLIS OMPYX0207 2006 ACS on STN (Continued)




IN 210915-01-1 CAPLIS
 ON 1,5-Diphenylacetamidoamide, 4-[[4-(6-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(1,1-dimethylethyl)-N-hydroxy-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IN 210915-00-3 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridinylmethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



IN 210915-94-4 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2-pyridinylmethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANWER 14 0F 17 CAPLIS OMPYX0207 2006 ACS on STN (Continued)




IN 210915-97-5 CAPLIS
 ON 1,5-Diphenylacetamidoamide, 4-[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IN 210915-90-4 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



IN 210915-00-9 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(6-methylpiperidin-2-yl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.

19 ANWER 14 0F 17 CAPLIS OMPYX0207 2006 ACS on STN (Continued)




IN 210915-06-5 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(6-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(4-methylpiperidin-2-yl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 210915-06-6 CAPLIS
 ON 2-Piperazinylacetamidoamide, 1-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-(2,2,2-trifluoroethyl)-, (3R)- (CA INDEX NAME)



IN 210915-07-7 CAPLIS
 ON 2-Piperazinylacetamidoamide, 4-[[4-(4-chlorophenyl)-1-piperidinyl]sulfonyl]-3-(hydroxymethyl)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.




L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)

IN 210916-14-6 CAPLIS
CN 2-Piperazinecarboxylic acid, 1-[[4-(5-oxo-1H-indol-3-yl)-1-methylsulfonyl]sulfonyl]-N-hydroxy-4-(2-pyrazolyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



IN 210916-16-9 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(6-fluoro-1-[[2-(1-methylsulfonyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-(dihydroxymethylcarboxyl)-, phenylmethyl ester (CA INDEX NAME)




IN 210916-11-9 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(6-fluoro-1-[[2-(1-methylsulfonyl)ethyl]sulfonyl]-1H-indol-3-yl]-1-piperidinyl]sulfonyl]-3-(dihydroxymethylcarboxyl)-, phenylmethyl ester (CA INDEX NAME)




L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)

L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)

CN 1,3-Piperazinedicarboxamide, 4-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)




IN 210916-10-4 CAPLIS
CN 1,3-Piperazinedicarboxamide, 4-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)




IN 210916-11-6 CAPLIS
CN 1,3-Piperazinedicarboxamide, 4-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 210916-13-7 CAPLIS
CN 1,3-Piperazinedicarboxamide, 4-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)




IN 210916-15-9 CAPLIS

L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)


IN 210916-42-4 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(6-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IN 210916-43-5 CAPLIS
CN 2-Piperazinecarboxamide, 4-oxo-1-[[4-(6-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IN 210916-44-6 CAPLIS
CN 1,3-Piperazinedicarboxamide, 4-[[4-(6-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)




IN 210916-45-7 CAPLIS
CN 1-Piperazinecarboxylic acid, 4-[[4-(6-fluoro-3-methylphenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-3-(1-methylsulfonyl)- (CA INDEX NAME)




L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)

L9 ANKER 14 OF 17 CAPLIS 06/19/2007 2006 ACS on STN (Continued)


CN 1,3-Piperazinedicarboxamide, N1-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-N1-dimethyl-, (2R)- (CA INDEX NAME)




IN 210916-77-1 CAPLIS
CN 2-Piperazinecarboxamide, 4-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



IN 210916-78-2 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4-(6-morpholinyl)carboxyl-, (2R)- (CA INDEX NAME)



IN 210916-79-3 CAPLIS
CN 2-Piperazinecarboxamide, 1-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy-4-(2,2-trifluoroethyl)- (CA INDEX NAME)




IN 210916-80-6 CAPLIS
CN 2-Piperazinecarboxamide, 4-[[1,3-dimethylamino]phenylsulfonyl]-1-[[4-(6-fluorophenyl)-5,6-dihydro-1(2H)-pyridinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)

19 ANKER 15 06 17 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)


thienyl]sulfonyl]-N-hydroxy-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-20-5 CAPLIS
CN 2-Fluorobenzoic acid, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(1-oxo-3-phenylpropyl)-, hydrochloride (1:1), (S)- (CA INDEX NAME)


Absolute stereochemistry.



● (S)

BN 200690-21-4 CAPLIS
CN 2-Fluorobenzoic acid, 4-[[3-(diethylamino)propyl]sulfonyl]-1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-, hydrochloride (1:1), (S)- (CA INDEX NAME)

Absolute stereochemistry.




● (S)

19 ANKER 16 06 17 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)


thienyl]sulfonyl]-N-hydroxy-4-(1-oxo-3-phenylpropyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 200690-26-1 CAPLIS
CN 2-Fluorobenzoic acid, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(1-oxo-3-phenylpropyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-27-2 CAPLIS
CN 2-Fluorobenzoic acid, 4-[[3-(diethylamino)propyl]sulfonyl]-1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-, (S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 200690-28-3 CAPLIS
CN 2-Fluorobenzoic acid, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(1-oxo-3-phenylpropyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.

19 ANKER 15 06 17 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)

BN 200690-22-7 CAPLIS
CN 2-Fluorobenzoic acid, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(1-oxo-3-phenylpropyl)-2-propenyl-], hydrochloride (1:1), (S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



● (S)


BN 200690-23-8 CAPLIS
CN 2-Fluorobenzoic acid, 4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-N-methyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 200690-24-9 CAPLIS
CN 2-Fluorobenzoic acid, 4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-N-methyl-, (S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 200690-25-0 CAPLIS

19 ANKER 16 06 17 CAPLIS OMPYRIGHT 2006 ACS on STM (Continued)




BN 200690-29-4 CAPLIS
CN 2-Fluorobenzoic acid, N-hydroxy-1-[[5-(4-methoxyphenyl)-2-thienyl]sulfonyl]-4-(methylsulfonyl)-, (S)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-30-7 CAPLIS
CN 2-Fluorobenzoic acid, N-hydroxy-1-[[5-(4-methoxyphenyl)-2-thienyl]sulfonyl]-4-(methylsulfonyl)-, (S)- (CA INDEX NAME)


Absolute stereochemistry.



BN 200690-31-8 CAPLIS
CN 2-Fluorobenzoic acid, 4-[[4-amino-4-oxobutyl]sulfonyl]-N-hydroxy-1-[[5-phenyl-2-thienyl]sulfonyl]-, (S)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS OMPKRIGHT 2006 ACS on STN (Continued)




BN 200690-32-9 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-1-[(4-pyridyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-33-0 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-1-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



BN 200690-34-1 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-1-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS OMPKRIGHT 2006 ACS on STN (Continued)




BN 200690-38-8 CAPLIS
CN 1,3-bisacetic acidamide, 4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-39-6 CAPLIS
CN 1,3-bisacetic acidamide, N-hydroxy-1-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



BN 200690-40-9 CAPLIS
CN 1,3-bisacetic acidamide, 4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS OMPKRIGHT 2006 ACS on STN (Continued)




BN 200690-36-3 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-1-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-36-3 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-1-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



BN 200690-37-4 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, 1-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-methylphenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS OMPKRIGHT 2006 ACS on STN (Continued)




BN 200690-41-0 CAPLIS
CN 1,3-bisacetic acidamide, 4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-42-1 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, 1-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200690-43-2 CAPLIS
CN 2-Fluoro-1,3-bisacetic acidamide, N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-1-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[6-(4-fluorophenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 0F 17 CAPLUS OFFRIGHT 2006 ACS on STM (Continued)



IN 200690-44-3 CAPLUS
CN Carbamic acid, 2-[[[2-(2-phenyl-2-thienyl)sulfonyl]ethyl]-1-phenyl]ester (HCl)
(A INDEX NAME)

Absolute stereochemistry.




IN 200690-45-4 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[(5-phenyl-2-thienyl)sulfonyl]-4-[[2-(4-tert-butyl-4-oxo-2-phenylthio)propyl)sulfonyl]], hydrochloride (1:1), (Cl-) (A INDEX NAME)

Absolute stereochemistry.




L9 ANKER 16 0F 17 CAPLUS OFFRIGHT 2006 ACS on STM (Continued)




IN 200690-49-8 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(4-ethoxyphenyl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (S)- (A INDEX NAME)

Absolute stereochemistry.




IN 200690-50-1 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(4-ethoxyphenyl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (R)- (A INDEX NAME)

Absolute stereochemistry




IN 200690-51-2 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(4-ethoxyphenyl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (S)- (A INDEX NAME)

Absolute stereochemistry.



IN 200690-52-3 CAPLUS


L9 ANKER 16 0F 17 CAPLUS OFFRIGHT 2006 ACS on STM (Continued)



● HCl


IN 200690-46-1 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[(5-2-oxoaminyl)-2-thienyl)sulfonyl]-4-(methylsulfonyl)-, (S)- (A INDEX NAME)

Absolute stereochemistry.



IN 200690-47-6 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[[6-(4-tert-butyl-4-oxo-2-phenylthio)propyl)sulfonyl]-, (R)- (A INDEX NAME)

Absolute stereochemistry.




IN 200690-48-7 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(1,3-benzodioxol-5-yl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (R)- (A INDEX NAME)

Absolute stereochemistry.




L9 ANKER 16 0F 17 CAPLUS OFFRIGHT 2006 ACS on STM (Continued)
CN 2-Piperazinecarboxamide, 1-[[6-(4-[[2-(4-methylthio)phenyl]-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (S)- (A INDEX NAME)

Absolute stereochemistry.




IN 200690-53-4 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(3-fluoro-4-methoxyphenyl)-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (R)- (A INDEX NAME)

Absolute stereochemistry.



IN 200690-54-5 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[[6-(2-methoxyphenyl)-2-thienyl)sulfonyl]-4-(methylsulfonyl)-, (R)- (A INDEX NAME)


Absolute stereochemistry.




IN 200690-55-6 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[6-(4-[[2-(4-methylthio)phenyl]-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (R)- (A INDEX NAME)

Absolute stereochemistry.


12 ANSERS 15 OF 17 CAPSIS COPYRIGHT 2006 ACS on STM (Continued)



IN 200690-16-1 CAPLIS
 CN 2-Piperazinecarboxamide, N-hydroxy-4-[(methylsulfonyl)-1-[[5-[4-
 [(methylsulfonyl)oxy]phenyl]-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry.




PN 200690-57-8 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[[5-(2,4-difluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry...




RX 200690-58-9 CAPLUS
 CN 2-Fibrazinincarboxamide, 1-[[5-[4-(cyanomethoxy)phenyl]-2-thienylsulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry


L9 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RX 200690-62-5 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[5-(2,3-dihydro-5-benzofuranyl)-2-thienylsulfonyl]-N-hydroxy-4-(methylsulfonyl)-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry



RX 209690-63-6 CAPLUS
 CN 2-Piperazinecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[[5-(4-phenoxyphenyl)-2-thienyl]sulfonyl]-, (R)- CCA INDEX NAME
 Absolute stereochemistry




RN 200690-64-7 CAFUS
 CN 2-[Pterazin-6-carboxamide, N-(hydroxy)-]-(3-[(3-methyl-1,3,4-oxadiazol-2-yl)-2-thienyl)sulfonyl]-4-(methylsulfonyl)-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry




RV 200620-EE-8 CAPLUS


L2 ANSWER 15 OF 17 CAPSULE COPYRIGHT 2006 ACS on STM (Continued)



RN 200690-19-0 CAPLUS
 CN Benzoic acid, 4-[5-[[[2(R)-3-[(hydroxyamino)carbonyl]-4-(methylsulfonyl)-1-piperazinyl]sulfonyl]-2-thienyl]-, methyl ester (CA INDEX NAME)
 Absolute stereochemistry.




IN 200990-60-3 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[(5-[3,1'-biphenyl]-4-yl-2-thienyl)sulfonyl]-N-hydroxy-4-(methylsulfonyl)-. (2S)- (CA INDEX NAME)




RN 200690-61-4 CAPLUS
 CN 2-Piperazinecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[[[5-(4-pyridinyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry.

19 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
CN 2-Piperanecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[[[3-(3-phenyl-
1,3,4-oxadiazol-2-yl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.



RN 200990-66-9 CAFLUS
 CN 2-[Piperazin-2-ylcarbamate, N-hydroxy-4-(methylsulfonyl)-1-[[5-(2-thiazolyl)-2-thienylsulfonyl]-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry.




IN 200990-67-0 CAPLUS
 CN 2-Piperazinecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[(5-phenyl-1,3,4-thiadiazol-2-yl)sulfonyl]-, (2R)- (CA INDEX NAME)
 Absolute stereochemistry




IN 2006/00-00-1 CAPJUS
CN 2-Piperazinecarboxamide, N-hydroxy-4-(methylsulfonyl)-1-[(4-(2-thienyl)phenyl)sulfonyl]-, (Z)- (CA INDEX NAME)
Absolute microchemistry

L9 ANWER 16 06 17 CAPLIS OMFYK182T 2006 ACS on STM (Continued)




RN 200690-49-2 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[(5-phenyl-2-thienyl)sulfonyl]-2-thienylmethyl-1-[(5-phenyl-2-thienyl)sulfonyl], (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 200690-10-6 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[(5-phenyl-2-thienyl)sulfonyl]-4-(1-phenyl-2-thienylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 200690-71-6 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[(methylpropylamino)sulfonyl]-1-[(5-phenyl-2-thienyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry

L9 ANWER 16 06 17 CAPLIS OMFYK182T 2006 ACS on STM (Continued)
(1-[(5-phenyl-2-thienyl)sulfonyl]-1-[(5-phenyl-2-thienyl)sulfonyl], hydrochloride (1), (2R)- (CA INDEX NAME)


Absolute stereochemistry



● HCl

RN 200690-75-0 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[(2-[(1H-imidazol-2-ylthio)propyl]methyl)-1-[(5-phenyl-2-thienyl)sulfonyl]-, hydrochloride (1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 200690-76-1 CAPLIS
CN 1-Piperazinecarboxylic acid, 2-[1-(hydroxymethyl)carboxyl]-4-[(5-phenyl-2-thienyl)sulfonyl]-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

L9 ANWER 16 06 17 CAPLIS OMFYK182T 2006 ACS on STM (Continued)




RN 200690-72-4 CAPLIS
CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-N-hydroxy-1-[(5-phenyl-2-thienyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 200690-73-4 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-1-[(5-phenyl-2-thienyl)sulfonyl]-4-[(2-phenyl-2-thienylthio)propyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 200690-74-9 CAPLIS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[(3-[(4-methyl-4H-1,2,4-triazol-3-ylthio)propyl]methyl)-1-[(5-phenyl-2-thienyl)sulfonyl]-, (2R)- (CA INDEX NAME)

L9 ANWER 16 06 17 CAPLIS OMFYK182T 2006 ACS on STM (Continued)




RN 200690-77-0 CAPLIS
CN 1,3-Piperazinecarboxamide, N-methyl-4N-hydroxy-4-[(5-phenyl-2-thienyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 200690-78-3 CAPLIS
CN 2-Piperazinecarboxamide, 1-[(5-[(4-fluorophenyl)-2-thienyl]methyl)-N-hydroxy-4-[(5-phenyl-2-thienylthio)propyl]methyl]-, hydrochloride (1), (2R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl


19 ANWER 15 OF 17 CAPLIS OMPRIGHT 2006 ACS on STM (Continued)
 IN 200690-19-4 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[2-(4-methyl-4H-1,2,4-triazol-2-yl)thio]propyl]sulfonyl]-, hydrochloride (1:1), (2S)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-10-1 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[2-(4-methyl-4H-1,2,4-triazol-2-yl)thio]propyl]sulfonyl]-, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-11-8 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[2-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-3-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy, hydrochloride (1:1), (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-10-2 CAPLIS
 CN 1-pyrazole, N-[[2S)-4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-3-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IN 200690-16-3 CAPLIS
 CN 1,3-Piperazinedicarboxamide, N2-[[2S)-amino-2-methyl]-4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N2-hydroxy, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-17-4 CAPLIS
 CN 1,3-Piperazinedicarboxamide, 4-[[2S)-4-(4-fluorophenyl)-2-thienyl]sulfonyl]-N2-hydroxy-N2-(2-methoxyethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




19 ANWER 15 OF 17 CAPLIS OMPRIGHT 2006 ACS on STM (Continued)



● HCl


IN 200690-10-9 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[2-pyrrolyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-10-0 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[eth[ylamino]sulfonyl]-1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-14-1 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(1-piperidyl)sulfonyl-, (2R)- (CA INDEX NAME)

19 ANWER 16 OF 17 CAPLIS OMPRIGHT 2006 ACS on STM (Continued)




IN 200690-18-5 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[eth[ylamino]sulfonyl]-N-hydroxy-1-[[5-(4-(trifluoromethyl)phenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IN 200690-19-6 CAPLIS
 CN 2-Piperazinecarboxamide, N-hydroxy-6-[[meth[ylsulfonyl]amino]sulfonyl]-1-[[5-(4-(trifluoromethyl)phenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IN 200690-10-9 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[dimethylamino]sulfonyl]-N-hydroxy-1-[[5-(4-(trifluoromethyl)phenyl)-2-thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



19 ANWER 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)


IN 200690-91-0 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-4-
 [(dimethylamino)amino]-9-hydroxy-, ClO⁻ (CA INDEX NAME)

Absolute stereochemistry




IN 200690-92-1 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-4-
 [(4-thiomethylamino)amino]-9-hydroxy-, ClO⁻ (CA INDEX NAME)

Absolute stereochemistry




IN 200690-92-2 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-[(1H-1,2,4-triazol-5-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)

Absolute stereochemistry




19 ANWER 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)

Absolute stereochemistry




IN 200690-91-6 CAPLIS
 ON 2-Piperazinecarboxylic acid, 4-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-3-
 [(hydroxyamino)caronyl]-, methyl ester, ClO⁻ (CA INDEX NAME)

Absolute stereochemistry



IN 200690-92-7 CAPLIS
 ON 2-Piperazinecarboxamide, 4-[(dimethylamino)amino]-1-[[5-(4-
 chlorophenyl)-2-thienyl]sulfonyl]-9-hydroxy-, ClO⁻ (CA INDEX NAME)

Absolute stereochemistry




IN 200690-99-8 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-[(1H-1,2,4-triazol-5-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)

Absolute stereochemistry

19 ANWER 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)


IN 200690-94-0 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-(4-methyl-5H-2,4-triazol-3-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)

Absolute stereochemistry



IN 200690-95-4 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-(1H-imidazol-2-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)


Absolute stereochemistry



IN 200690-96-5 CAPLIS
 ON 2-Piperazinecarboxamide, 4-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-1-
 [[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-hydroxy-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)


19 ANWER 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)

Absolute stereochemistry



IN 200691-00-4 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-(4-methyl-5H-2,4-triazol-3-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)


Absolute stereochemistry



IN 200691-01-5 CAPLIS
 ON 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-9-
 hydroxy-4-[[3-(1H-imidazol-2-ylthio)propyl]amino]amino]-, hydrochloride
 (1:1), ClO⁻ (CA INDEX NAME)


Absolute stereochemistry

L9 ANSWER 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)




IN 206691-00-6 CAPLAS
CN 2-Piperazinecarboxamide, 1-[[[5-(4-cyanophenyl)-2-thienyl]sulfonyl]-4-
[[dimethylamino)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



BN 200691-00-7 CAPLUS
CN 2-Piperazinecarboxamide, 1-[[5-[4-(cyanomethyl)phenyl]-2-thienyl]sulfonyl]-4-[(dimethylamino)sulfonyl]-N-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry



IN 200601-04-6 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-1-[[5-(3-fluoro-4-methoxybenzyl)-2-thienyl]sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry

L9 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)




RW 200601-10-6 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[2-[[[methylsulfonyl]amino]ethyl]sulfonyl]-, (2R)- (CA INO60 NMR)

Absolute stereochemistry



IN 200001-11-7 CAPLUS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[[2-
[methoxy(methylamino)ethyl]amino]-1-[(5-phenyl-2-thienyl)ethyl]


Absolute stereochemistry.



RN 200601-10-8 CAPLOS
CN 2-Piperazinecarboxamide, N-hydroxy-4-[[2-
[(methylsulfonyl)amino]ethyl]sulfonyl]-1-[[5-[4-(trifluoromethyl)phenyl]-2-
thienyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry

19 ACS/RRR 15 OF 17 CAPLIS COPYRIGHT 2006 ACS on STM (Continued)




BN 200691-06-0 CAFIUS
 CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-N-hydroxy-1-[(4-phenoxymethyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry



IN 200691-07-1 CAPLUS
 CN 1,5-Piperazinedicarboxamide, 4-[[[5-(4-cyanophenyl)-2-thienyl]sulfonyl]-N-ethyl-N3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry



ON 2-Piperazinecarboxamide, 4-[[2-(acetylamino)ethylsulfonyl]-1-[[5-(4-


Absolute stereochemistry

L9 ANSWER 15 OF 17 CAPUS COPYRIGHT 2008 ACS on STM (Continued)




IN 200601-15-9 CAPJUS
 CN 2-Piperazinecarboxamide, 1-[[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-3-hydroxy-4-[[2-[(methylsulfonyl)amino]ethyl]sulfonyl]-, C20H- 6CA INDEX NAME

Absolute stereochemistry



IN 208091-14-0 CAFUS
CN 2-Piperazinecarboxamide, 1-[[[5-(4-ethoxyphenyl)-2-thienyl]sulfonyl]-8-hydroxy-4-{[2-(methoxysulfonyl)amino]ethyl}sulfonyl]-, (2R)-, (1S, 2R, 3R, 4R, 5R, 6R, 7R, 8R)-


Absolute stereochemistry



IN 300691-15-1 CAPLUS
ON 2-Piperazinecarboxamide, 1-[[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-8-hydroxy-4-[[2-[(2-pyridinyl)sulfonyl]amino]ethyl]sulfonyl]-, (2S)- (6)


Absolute stereochemistry

L9 ANKER 16 OF 17 CAPLIS OMFYRIGHT 2006 ACS on STM (Continued)




IN 200691-16-2 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-N-[[2-[(dimethylamino)ethyl]amino]ethyl]sulfonyl]-N-hydroxy-, CRO- (CA INDEX NAME)

Absolute stereochemistry.



IN 200691-17-3 CAPLIS
 CN Carbanic acid, [2-[[[3,6]-4-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-2-(hydroxymethyl)carbamoyl]-1-piperazinyl]sulfonyl]ethyl]-, methyl ester (XC1) (CA INDEX NAME)


Absolute stereochemistry.



IN 200691-18-4 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-[[2-(2-pyridinyl)carbamoyl]amino]ethyl]sulfonyl]-, CRO- (CA INDEX NAME)


Absolute stereochemistry

L9 ANKER 15 OF 17 CAPLIS OMFYRIGHT 2006 ACS on STM (Continued)




IN 200691-19-5 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[2-(2-aminoamino)ethyl]sulfonyl]-1-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-N-hydroxy-, CRO- (CA INDEX NAME)

Absolute stereochemistry.



IN 200691-21-9 CAPLIS
 CN Glycine, N-[[[3,6]-4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-2-[[2-(2-aminoamino)ethyl]sulfonyl]-1-piperazinyl]carbamoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



IN 200691-50-5 CAPLIS
 CN 2-Piperazinecarboxamide, N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-4-(methylsulfonyl)-, CRO- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS OMFYRIGHT 2006 ACS on STM (Continued)




IN 200691-94-6 CAPLIS
 CN 2-Piperazinecarboxamide, N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-4-(methylsulfonyl)-, CRO- (CA INDEX NAME)

Absolute stereochemistry.




IN 200691-96-7 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[2-(dimethylamino)ethyl]sulfonyl]-N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-, CRO- (CA INDEX NAME)

Absolute stereochemistry



IN 200691-96-8 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[2-(dimethylamino)ethyl]sulfonyl]-N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-, CRO- (CA INDEX NAME)


Absolute stereochemistry.



IN 200691-97-9 CAPLIS


L9 ANKER 16 OF 17 CAPLIS OMFYRIGHT 2006 ACS on STM (Continued)
 CN 2-Piperazinecarboxamide, N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-4-(methylsulfonyl)-, CRO- (CA INDEX NAME)

Absolute stereochemistry.




IN 200691-98-9 CAPLIS
 CN 2-Piperazinecarboxamide, N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-4-[[2-(2-pyridinyl)carbamoyl]amino]ethyl]sulfonyl]-, CRO- (CA INDEX NAME)

Absolute stereochemistry.



IN 200691-99-1 CAPLIS
 CN 2-Piperazinecarboxamide, 4-[[2-(2-aminoamino)ethyl]sulfonyl]-N-hydroxy-1-[[5-(4-hydroxyphenyl)-2-thienyl]sulfonyl]-, CRO- (CA INDEX NAME)


Absolute stereochemistry.



IN 200692-00-7 CAPLIS
 CN 2-Piperazinecarboxamide, 1-[[5-(3-fluoro-4-hydroxyphenyl)-2-thienyl]sulfonyl]-N-hydroxy-4-(methylsulfonyl)-, CRO- (CA INDEX NAME)


Absolute stereochemistry.

L9 ANKER 16 OF 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)



RV 19250-19-4 CAPLIS
ON 2-Fluoro-1-[[4-(4-fluorophenyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)

Absolute stereochemistry




RV 19250-99-9 CAPLIS
ON 2-Fluoro-1-[[4-(4-phenylphenyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)




RV 19250-14-4 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)

Absolute stereochemistry




L9 ANKER 16 OF 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)

RV 19250-15-7 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)



RV 19250-17-9 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)


Absolute stereochemistry



● HCl

RV 19250-18-0 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)


Absolute stereochemistry



RV 19250-19-1 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)

Absolute stereochemistry


L9 ANKER 16 OF 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)




● HCl

RV 19250-10-4 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)


Absolute stereochemistry



RV 19250-21-8 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)




RV 207795-09-2 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)




RV 207795-09-3 CAPLIS

L9 ANKER 16 OF 17 CAPLIS CONFIDENT 2006 ACS on STM (Continued)

RV 207795-10-6 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)



RV 207795-10-6 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)




RV 207795-11-7 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)



RV 207795-14-0 CAPLIS
ON 2-Fluoro-1-[[4-(4-(4-chlorophenyl)phenyl]sulfonyl)-3-(hydroxymethyl)phenyl]sulfonyl]-N-hydroxy-4-methylpiperidin-3-ylidene (CA INDEX NAME)

Absolute stereochemistry




RV 207795-15-1 CAPLIS


L9 ANWER IT OF IT CAPLSE OMPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



BN 192329-49-0 CAPLSE
CN 1-Fluorobenzoic acid, 4-[[4-(4-chlorophenyl)phenyl]sulfonyl]-2-[(hydroxyamino)acetyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)
Absolute stereochemistry.




BN 192329-50-3 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.




● HCl

BN 192329-51-4 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry


L9 ANWER IT OF IT CAPLSE OMPYRIGHT 2006 ACS on STN (Continued)




BN 192329-69-4 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-bromophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.



BN 192329-70-7 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.




BN 192329-71-8 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry




BN 192329-72-6 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.

L9 ANWER IT OF IT CAPLSE OMPYRIGHT 2006 ACS on STN (Continued)




● HCl

BN 192329-60-5 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)




BN 192329-65-0 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.




BN 192329-69-3 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)phenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.


L9 ANWER IT OF IT CAPLSE OMPYRIGHT 2006 ACS on STN (Continued)




BN 192329-74-1 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.



BN 192329-75-2 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry.



BN 192329-76-3 CAPLSE
CN 2-Fluorobenzoic acid, 1-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-hydroxy-5,5-dimethyl-1-oxo-, (2R)- (CA INDEX NAME)
Absolute stereochemistry




BN 192329-99-0 CAPLSE
CN 2-Fluorobenzoic acid, N-hydroxy-1-[(4-phenylphenyl)sulfonyl]- (CA INDEX NAME)

19 ANKER 17 07 17 CAPLIS OMPKIGBT 2006 ACS on STM (Continued)




TX 19CSD0-14-4 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester, (S)- (CA INDEX NAME)


Absolute stereochemistry



RX 19CSD0-15-7 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)




RX 19CSD0-16-8 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)




RX 19CSD0-17-9 CAPLIS

19 ANKER 17 07 17 CAPLIS OMPKIGBT 2006 ACS on STM (Continued)

Absolute stereochemistry




RX 19CSD0-21-4 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)



RX 19CSD0-22-6 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry




12 19CSD0-99-00 19CSD0-23-7P
RE: KCT (Reactant), STM (Synthetic preparation), PREP (Preparation), NACT (Reactant or reagent)
Generation of heterocyclic metalloproteinase-inhibitor antitumor agents and antiarthritics

RX 19CSD0-99-00 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

19 ANKER 17 07 17 CAPLIS OMPKIGBT 2006 ACS on STM (Continued)

CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry



● HCl


RX 19CSD0-18-0 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry



RX 19CSD0-19-3 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry



● HCl


RX 19CSD0-20-4 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

19 ANKER 17 07 17 CAPLIS OMPKIGBT 2006 ACS on STM (Continued)



RX 19CSD0-25-7 CAPLIS
CN 2-[4-(4-fluorophenyl)phenyl]sulfonyl-3-(hydroxyamino)butanoic acid, 4-[[4-(4-fluorophenyl)phenyl]sulfonyl]-3-(hydroxyamino)butanoic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry



=> d his full

(FILE 'HOME' ENTERED AT 07:57:59 ON 21 DEC 2008)

FILE 'REGISTRY' ENTERED AT 07:58:16 ON 21 DEC 2008

```

L1  STRUCTURE UPLOADED
    D
L2  27 SEA SSS SAM L1
L3  1 SEA ABB=ON PLU=ON PIPERAZINE/CN
    D RSD
L4  1425189 SEA ABB=ON PLU=ON 46.383/RID
L5  367 SEA SUB=L4 SSS FUL L1
    D QUE L5 STAT
L6  238 SEA ABB=ON PLU=ON L5 AND ED<6/12/2002
L7  235 SEA ABB=ON PLU=ON L6 AND CAPLUS/LC
L8  3 SEA ABB=ON PLU=ON L6 NOT L7
    D 1-3 IDE CAN

FILE 'CAPLUS' ENTERED AT 08:03:47 ON 21 DEC 2008
L9  17 SEA ABB=ON PLU=ON L5
    D 1-17 BIB ABS HITSTR

```

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2008 HIGHEST RN 1087349-26-5

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	94.57	303.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.60	-13.60

STN INTERNATIONAL LOGOFF AT 08:06:07 ON 21 DEC 2008